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Ab   Antibody 
APC    Antigen presenting cell 
BCM   B-cell medium 
BCR    B-cell receptor 
B-LCL   B-lymphoblastoid cell line 
CFSE    Carboxyfluorescein diacetate succinimidyl ester 
CTLA4   Cytotoxic T lymphocyte-associated protein 4 
CV   Column volumes 
DC   Dendritic Cells 
EBV   Epstein Barr virus 
EDTA   Ethylenediaminetetraacetic acid 
FACS    Fluorescence activated cell sorting 
FBS    Fetal bovine serum 
FcRn    Neonatal Fc receptor 
FNAIT   Fetal and neonatal alloimmune thrombocytopenia 
FSC    Forward scattered light 
GALT   Gut associate lymphoid tissue 
HLA    Human leukocyte antigen 
HPA    Human platelet antigen 




HRP   Horseradish peroxidase 
IFN-γ    Interferon-γ 
Ig    Immunoglobulin 
IL-2    Interleukin-2 
IL-15    Interleukin-15 
IMDM   Iscove’s modified Dulbecco’s medium 
Irr.   Irradiated 
mAbs   Monoclonal antibodies 
MHC II   Major histocompatibility complex class II 
PBMC   Peripheral blood mononuclear cells 
PBS    Phosphate buffered saline 
PBSA 0.2 %   Phosphate buffered saline + 0.2 % bovine serum albumin 
PHA    Phytohemagglutinin 
SDS-PAGE  Sodium dodecyl sulphate-poly acrylamide gel electrophoresis 
SSC    Side scattered light 
TACE   Tumor Necrosis factor-α-Converting Enzyme 
TAPI-0  TNF-α Processing Inhibitor-0 
TCM   T-cell medium 
TCR    T-cell receptor 







Foetal and neonatal alloimmune thrombocytopenia (FNAIT) is a disease caused by the 
production of antibodies by the mother to the platelets of the foetus. The alloimmune (from 
mother to unborn child) response is caused by a P33L substitution in the Human Platelet 
Antigen-1a (HPA-1a) in a homo- or heterozygous HPA-1a foetus, in a homozygous HPA-1b+ 
mother. Antigen presenting cells (APCs) of the mother recognize this substitution, often 
through the specific MHC II molecule called DRB3*01:01, and activate anti-HPA-1a+ platelet 
antibody production. Maternal platelets freely cross the placenta and induce platelet 
destruction in turn causing symptoms varying in severity like; purpura or cephalohematoma 
in the foetus. The production of maternal anti-platelet antibodies is assisted by HPA-1a 
specific T-cells able to bind the DRB3*01:01-HPA-1a antigen complex.  
Studies have shown that DRB3*01:01 can also bind some other antigen peptides with 
hydrophobic residues amino acids at position 33 like valine, by which T-cells can be 
activated. Therefor it may be possible to find antigen from other (animal) sources that can 
also excite HPA-1a specific T-cells. Rabbit integrin β3 has homology with HPA-1a peptide 
recognized by HPA-1a specific T-cells except for a P33V substitution.  
In this study 3 main aims will be followed, To determine if HPA-1a specific antibodies can 
bind rabbit platelets. 2) Examine whether rabbit platelets can activate HPA-1a specific T-
cells. 3) To examine whether HPA-1a specific T cells can specifically recognize and be 
activated by rabbit integrin β3 protein, rabbit integrin β3 therefor needs to be isolated.. The 
rationale being to determine if rabbit integrin β3 is a viable antigen for oral tolerance 
induction therapy development in the long term. 
A protein database was used for animal and human integrin β3 comparison for examination of 
theoretical binding capabilities of DRB3*01:01 and mAb 26.4 to various integrins and 
showed rabbit integrin β3 as compatible for both. TNF-α and proliferation assays were 
performed and showed rabbit integrin β3 is a viable activator of HPA-1a specific cells both 
for immediate and long term T-cell responses. integrin β3 isolation via affinity 
chromatography was attempted but shown to be unsuccessful via western blot. Thus, rabbit 
integrin β3 in platelet, protein or peptide form could potentially be used oral tolerance therapy 









1.1 Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) 
 
FNAIT is caused by the maternal formation of antibodies to human platelet antigen (HPA) 
phenotypically different from the HPA the mother carries, which then cross the placenta and 
destroy the fetal platelets (1). The maternal activation of anti-platelet antibody production by 
the immune system is induced by fetomaternal transfusions (or fetomaternal hemorrhage). 
This exposes the maternal antigen-presenting cells with the allogenic HPA (2, 3). In 1 in 800-
1000 births, this mismatch in HPA occurs in pregnancies and these maternally produced anti-
platelet alloantigen antibodies cross the placenta and induce platelet destruction. Causing an 
array of symptoms including: petechiae, purpura or cephalohaematoma at birth, associated 
with major risk of intracranial haemorrhage, which can lead to death or neurological sequelae 
in the child (2, 3). Recognition of allogenic HPA-1a, the most common HPA in the western 
world, is caused by a very specific difference in the integrin β3 amino acid chain: L33P. The 
change in amino acid causes the immune system of the HPA-1b/b individual to react to the 
HPA-1a/b or a/a individual (or also other genotypically different HPA variants) (1, 4-6). 
Additionally, many HPA-1a immunized women carry the MHC class II allele HLA-
DRB3*01:01, indicating that anti-HPA-1a antibody production is assisted by T-cell responses 
restricted to this specific allele (6).  
 
1.2 Human Platelet Antigens 
 
Platelets present various platelet surface protein that have been found to be important in 
platelet specific auto- alloimmune diseases. They often exist in 2 or more phenotypic types 
that have single nucleotide polymorphisms (SNP’s), which may be processed into antigens 
and are called human platelet antigens (HPA). These HPA can induce auto- or alloimmune 
responses when introduced to an individual through activation of the adaptive immune 
system (7). HPA-1 is the antigen associated with FNAIT as at least 3 phenotype HPA-1a, b 




1.2.1 Integrin structure and function. 
 
HPA-1 part of integrin β3, is a member of the integrin receptor family being adhesion 
molecules that facilitate interaction between cell and other cell, extracellular matrix or 
pathogen (10). Integrins regulate many biological functions including cell differentiation, 
wound healing and cell migration. Integrin consist generally of two non-covalently associated 
α and β subunit with long extracellular, single-spanning transmembrane domains and short 
cytoplasmic domains (10, 11). Integrins can relay signals bidirectionally across the plasma 
membrane, by ligand binding on the globular end of the extracellular domain and changing 
their conformation into higher or lower affinity positions (10, 12). The conformation of 
integrins is for example important in its active form for the adhesion to and exiting from 
blood vessels or in integrin β3 coagulation (7, 12). 
 
1.2.2 Integrin β3 connection with FNAIT. 
 
HPA-1, located on the membrane glycoprotein (GP) IIIa also called integrin β3, which 
mainly is found in three different variants, determined by a diallelic antigen system. HPA-1’s 
three known phenotypes are, HPA-1a, 1b and 1c which respectively have a leucine, proline or 
valine at amino acid position 33 (8, 9). HPA-1c has been only reported once in the literature. 
This specific alloantigen is found with a 98% HPA-1a variant (a/a or a/b) ratio in Caucasians 
and in a 2% ratio HPA-1b (b/b), where the only difference in the amino acid chain is an L33P 
substitution (leucine to proline in the 33th position) (13). This SNP could in an HPA-1a+ 
fetus in pregnant HPA-1bb mothers cause HPA-1a specific antibodies to be made. Integrin β3 
associates with 2 α variants; αIIb and αV (10). The αIIbβ3 receptor is found on platelets in 
quantities around 80.000 proteins per platelet, with the main function being platelet 
coagulation binding with fibrinogen, fibronectin, von Willebrand factor and vitronectin (7, 
10, 14). The αVβ3 receptor can also be found on platelets at a quantity of a few thousand per 
platelet and are otherwise found on endothelium and it binds mainly fibronectin, fibrinogen 
and vitronectin (7, 15). The location of these integrin receptors explains the symptoms seen 
in fetuses in mothers with an FNAIT antibody response. HPA-1a specific antibodies bind and 




cause thrombocytopenia and brain hemorrhaging, due to endothelium apoptosis, dependent 
on the type of HPA-1a specific alloantibodies (16). 
 
1.3 Major histocompatibility complex 
 
The human major histocompatibility complex (MHC) or human leukocyte antigen (HLA) 
class II are the molecules on immunologic cells that present peptide antigens to T-cells. The 
MHC II consists of non-covalently bound α- and β-chains, which are highly genetically 
polymorphic, except the DR α-chain. The MHC II isotypes an individual will present on 
immune cells is dependent on the haplotype, or inherited versions of the different DQ, DR 




DRB3*01:01 is highly associated with the immunization of HPA-1bb woman with HPA-1a 
(4, 18-20). Studies have shown that while DRB3*01:01 has a prevalence of ~28% in the 
normal population, the prevalence in alloimmunized women ~90-94% (4, 18-20). This link 
was further supported and examined by an article by Wu S. et al. where was found that L33 is 
one of three important anchoring motifs to HLA-DRB3*01:01 it. Where L33 binds 
significantly stronger than P33 (21). As well as an article by Parry C. S et al. where it was 
found that L33 binding to HLA-DRB3*01:01 is facilitated by a hydrophobic pocket in HLA-
DRB3*01:01 (22), and in two articles by Ahlen M. T et al. finding a link between FNAIT 
and HLA-DRB3*01:01 showing binding via indirect allorecognition (4, 6).  
 
1.3.2 Structure and Peptide Binding 
 
The normally canonical motif for binding pocket in other alleles of MHC includes P6 but is 
silent in DRB3 thus having the distinctive P1-P4-P9 motif (22). Binding pocket P1 is a large 




also very hydrophobic (22). The characteristic of the specific pockets as well as the general 
morphology of the binding groove of the MHC class II molecules postulates that only certain 
peptides with the residues matching the different pockets will be able to bind there. The P9 
binding pocket seems to have a determining role for the binding of  HPA-1a peptide to the 
DRA/DRB3*01:01 MHC class II molecule. Peptides in which substitutions introduced in 
other positions than P9 did not influence binding significantly while the P33 substitution was 
not able to bind DRB3*01:01 (4). P33 was likely unable to bind due to steric hindrance of a 
cyclic residue as well as not being hydrophobic indicating MHC restriction. 
 
1.4 T-cell Mediated Immune Responses against HPA-1a 
 
In response to an alloantigen like HPA-1a, a large amount of signals and mechanisms are 
initiated for antigen uptake, differentiation of B-cell in B-lymphoblast for antigen production 
and T-cell activation and maturation in T-helper cells (12). T-cells are an important part of 
the humoral response seen as main effector mechanism in FNAITs. Naïve T-helper cells are 
stimulated by APCs presenting HPA-1a antigen. Activated T-helper cells start expressing and 
excreting a plethora of chemokines, surface proteins and cytokines. Once the activated T-
helper cells have received sufficient stimulation by the MHC II-HPA-1a complex, B7 and 
cytokine they will start proliferation as well. Specific B-cells are meanwhile also presented 
with HPA-1a and starts to express various chemokines, surface proteins and cytokines as 
well. Activated B-cells travel from the follicle towards T-helper cells attracted to each other 
by chemokines. On interaction with the activated B-cell presents HPA-1a antigen to the 
activated T-helper cell and together with CD40 and cytokines induce B-cell proliferation and 
differentiation (12). B-lymphoblasts will then produce HPA-1a specific antibodies and 
undergo affinity maturation (12).  
 
1.4.1 T-cell activation and proliferation study. 
 
TNF-α secretion and proliferation are both import indicators of T-cell activation. Both have 
been used to measure the response of HPA-1a specific T-cells to HPA-1a and HPA-1b 




1b antigen both in PBMC from immunized women (23) and with clonal HPA-1a-specific 
CD4+ T cells generated from PMBC isolated from immunized women (6, 24). 
TNF-α is a pyrogen which is excreted on activated T-cells in its precursor membrane bound 
form. Tumor necrosis factor-α-converting enzyme (TACE) is a metalloproteinase that can 
cleave membrane bound TNF-α at the ala 76- val77 site (25). Only after TACE has cleaved 
the extracellular TNF-α section from its membrane-bound section is TNF-α truly 
extracellular excreted (25). TNF-α can bind either the TNFR1 non-immune cells or on 
immune cells, and activate its pyrogenic functions appropriate for each cell type. TNF-α 
Processing Inhibitor-0 (TAPI-0) is a metalloproteinase inhibitor specific for TACE (26) and 
TAPI-0 can prevent the precursor TNF-α from being released and solubilized. TNF-α will 
then remain, in its precursor form in the surface of the cell. TNF-α expression of a T-cell can 
then be stained for TNF-α and accurately measured by flow cytometry in an TNF-α excretion 
assay (Fig 1-1). 
Figure 1-1 TNF-α excretion assay mechanism.  
Upon T-cell activation by the three main signaling routs, MHC II-peptide complex to TCR, B7 interaction with CD28 
and cytokine stimulation, the T-cells starts excreting TNF-α. In 1. the TNF-α excretion assay is shown and in 2. the 
normal TNF-α excretion mechanism. Normally TNF-α will be cleaved from its transmembrane domain and do its 
effector function as a cytokine, in the assay however is TAPI-0 inhibiting TACE. TNF-α thus remains on the activated 




Carboxyfluorescein succinimidyl ester (CFSE) staining was first used in immunological 
studies studying the migration of immune cells because of its ability the bind cellular protein 
stably over long periods of time (27). CFSE’s stability and the fact that cellular proteins 
divide equally between the daughter cells made it an effective way of extracting information 
about the T-cells proliferation (28). CFSE staining is done with a compound called 
carboxyfluorescein diacetate succinimidyl ester which is not fluorescent in this state due to 
the two acetate groups present, but making the molecule highly permeable (27). The two 
acetate groups are rapidly removed by esterase’s present in the cells cytoplasm making the 
compound able to be fluorescent (27). The succinimidyl group allows the CFSE to create 
highly stable bonds with cellular protein binding to lysine residues (27). Carboxylfluorescein 
bound to protein in the cells gives the fluorophore its stability for up to several months and is 
only diminished by division of the stained cells (27, 28). Up to 8 cell divisions can be made 
visible before the CFSE is too diluted to be detected reliably by flow cytometry (Fig 1-2). 
Figure 1-2 Proliferation assay mechanism.  
Activated T-cells will start proliferating and this can be measured with a proliferation assay. CFSE is fluorophore able to 
bind protein in the T-cells, is stable over long periods of time and is equally divided between daughter cells upon cell 
division. The CFSE mechanism causes the fluorescence intensity to half on every division as shown in the top. The parent 
population (P) is the population not activated, while activated T-cells will proliferate and decrease their fluorescence 
intensity by half in every subsequent generation (G1, 2, 3). CFSE fluorescence intensity can be measured by flow cytometry 
and thus the parent and daughter cell generation can be plotted on a histogram. The parent generation is shown in red while 




1.5 Oral Tolerance 
 
Oral tolerance is the suppression of systemic immune responses to a specific antigen 
following oral administration of the antigen. Induction of oral tolerance depends on activation 
of gut immune system such that subsequent immune responses to tolerogenic antigen are 
suppressed (29). 
The main role of the gut associated lymphoid tissues (GALT) is maintaining tolerance 
towards the many food proteins, commensal microbiota and some other xenobiotics, while 
also protecting from the occasional pathogen (12, 29, 30). The GALT thus, has to choose and 
is able to react actively and passively to respectively harmful and benign foreign antigens.  
Generally the Peyer's patches are the initial site were antigens are detected and taken up by 
the immune system followed by presentation to multiple other types immune- or tolerogenic 
of T- and B-cells in the mesenteric lymph nodes (12, 29, 30).  
 
1.6 Anti-human integrin β3 antibodies.  
 
Four mono clonal antibodies (mAb) were used for the detection of HPA-1/integrin β3. Y2/51 
and AP3 have both been shown to be specific to integrin β3 but not HPA-1a (31, 32). Mab 
SZ21 has been shown previously to be pseudo specific. SZ21 is mainly specific to HPA-1a 
but has some affinity in a dose dependent manner for HPA-1b as well (5, 33). The mAb 26.4 
antibody has high affinity for HPA-1a but not for HPA-1b. The antibody was produced from 
an immortalized HPA-1a specific B-cell isolated from a HPA-1a immunized woman (5). 
Additionally is the epitope of mAb 26.4 at least in part specific for the same epitope 
recognized by the T-cell receptor (TCR) when the HPA-1a antigen is presented in 
DRA/DRB3*01:01. Mab 26.4 is known to be sensitive for amino acids in position 30, 32, 33, 






1.7 Rabbit integrin β3. 
 
The human integrin β3 gene ITGB3 on chromosome 17 and rabbit ITGB3 on chromosome 19 
show 81.79 % homology (35). Rabbit integrin β3 has similar functions in rabbits as it has in 
human. Protein alignment of the rabbit and human integrin β3 shows up to 95% homology 
with 750 identical amino acid position and 29 that are similar (36). The epitope associated 
with FNAIT in rabbit shows homology with the rare HPA-1c epitope. Which has a valine at 
amino acid position 33 instead of a leucine. (8). 
Figure 1-3 Alignment of human and rabbit integrin β3. 
Here the amino acid alignment of human and rabbit integrin β3 or shown. * represent the amino acids in that position being 
identical, while : means a similar type of amino acid is found in that position. An empty space signifies an amino acid substitution 
in rabbit integrin β3 of an amino acid not similar to human integrin β3.The human HPA-1a T cell epitope is highlighted. The 





1.8 Hypothesis and Aims of this Study. 
 
Recently found data from Immunology group at UiT showed that a similar immunological 
response might be produced by substitution of the Leucine with another small hydrophobic 
amino acid, like Valine in the HPA-1a T-cell epitope (4, 6, 21, 22). This specific amino acid 
sequence is found in the rabbit Integrin β3 and might thus be able to elicit similar responses 
from a human immune system (4). Many new discoveries have been made recently in oral 
tolerance and its uses in allergy reduction and application for autoimmune diseases. Oral 
tolerance may be induced by digested antigen presentation to the gut-associated lymphoid 
tissue. HPA-1a or rabbit Integrin β3 could following this line of thinking be used to induce 
oral tolerance in individuals at risk for FNAIT in the future (29). 
During this master the following objectives will be followed. 1) To determine if HPA-1a 
specific antibodies can bind rabbit platelets. 2) Examine whether rabbit platelets can activate 
HPA-1a specific T-cells. 3) To examine whether HPA-1a specific T cells can specifically 
recognize and be activated by rabbit integrin β3 protein, rabbit integrin β3 therefor needs to 
be isolated. The goals presented in this thesis have the long-term aim in mind; to prevent the 
occurrence or reduce symptoms of FNAIT by induction of oral tolerance against human 













2 Materials and Methods 
2.1 Materials and Reagents 
 
All reagents, buffers and media used are mentioned in Table 1 Appendix. And a list of all 
used antigens of different types are listed in Table 1. 
Table 1 Complete list of antigens used for T-cell stimulation during this master thesis. 
 
Name Antigen Type Amino acid Sequence 
of Interest* 
HPA-1a Platelet AWCSDEALPLGS 
 Protein AWCSDEALPLGS 
L33 Peptide AWCSDEALPLGS 
HPA-1b Platelet AWCSDEALPPGS 
Rabbit integrin β3 Platelet AWCSDEALPVGS 
Rabbit integrin β3 Protein AWCSDEALPVGS 
lolP1 Peptide VWRIDTPDKLTG 
 
B-cell medium (BCM) is a mixture of Iscove’s Modified Dulbecco’s Medium (IMDM; 
Lonza BioWhittaker, Verviers, Belgium) with 10 % Fetal Bovine Serum (FBS; Gibco by Life 
Technologies), 1 % PenicillinStreptomycin (Sigma-Aldrich).  
And T-cell medium (TCM) consists of Iscove’s Modified Dulbecco’s Medium (IMDM; 
Lonza BioWhittaker, Verviers, Belgium) with 10 % Fetal Bovine Serum (FBS; Gibco by Life 
Technologies), 4 % human HPA-1bb serum and 1 % PenicillinStreptomycin (Sigma-
Aldrich). All media used were sterile filtrated using Nalgene – RapidFlow filter bottles and 
then stored at 4 °C. Human serum used in TCM was prepared from plasma from HPA-1a- 
donors obtained from the blood bank at UNN Tromsø. The anticoagulant CaCl2 was added to 
the plasma at 1:100 ratio and incubated overnight at 37 °C. The following day all fluid with 
clumping was centrifuged for 15 min at 3000 g and the serum supernatant was transferred to 
a new tube. To inactivate the complement system in the serum a heat inactivation treatment 
was performed leaving the tubes in a water bath for 25 min at 56 °C. The heat-inactivated 
serum is stored at -70 °C and thawed when needed for medium preparation. 
Peptides used were all obtained from Eurogentec (Liege, Belgium). Platelets were obtained 
from donors and are further discussed in the Cells and Platelets section. All antigens used for 




origin. lolP1 peptide was used in the T-cell activation assay as a negative control exploiting 
its ability to stably bind in the HLA-DRB3*01:01 binding pocket without activating the 
HPA-1a specific T-cells (21, 37). The peptides were dissolved in 40% water and 60% ethanol 
stored at –20°C 
 
2.2 Cells and Platelets 
 
The current study was performed without need of approval of the Regional Committee for 
Medical Research Ethics, North-Norway. Buffy coats obtained from the blood bank at UNN 
were from consenting anonymous donors and only used for research purposes, thus not in 
need of REK approval. 
 
2.2.1 HPA-1a specific T-cell and B-LCL clones 
 
HPA-1a specific T-cell clones that were used during the study were previously isolated and 
stored in nitrogen storage at the Immunology Research group at UiT as described by Ahlen 
M.T et.al. (38, 39).  
HLA-DRB3*01:01+ B-LCL (D4BL4 and D48BL6) used during the study were previously 
isolated and stored in nitrogen storage at the Immunology Research group at UiT as 
described by Ahlen M.T et.al. (38, 39). All B-cell and T-cell clones Epstein-Barr virus (EBV) 




Platelets used were isolated from HPA-1a/a and HPA-1b/b anonymous individuals donating 
blood at   the Diagnostic Clinic at the University Hospital of North Norway (. All blood 
samples obtained for this purpose were from consenting anonymous donors and only used for 
research purposes. Additionally animal platelets used in this study were bought from Charles 






Cells in cryopreservation can be stored for up to several years without the need to keep the 
cells in culture. Cell are suspended in a medium that protects the cell from the rapid freezing 
process, cooling the samples to -196 °C. Samples are pelleted and resuspended in freeze 
medium consisting of 90 % FBS and 10 % DMSO. Freezing cells at high cell concentration is 
recommended and were usually between 1-10*106 cells/ 1,5 mL. Cryotubes with 1,5 mL of 
cells suspension are pre-cooled -1°C/minute to -70 °C and within a week transferred to 
nitrogen storage at -196 °C. Samples were thawed quickly placing the cryotubes in a 50 °C 
water bath until only a fraction of the sample is frozen. The last frozen fraction was thawed 
with body heat and quickly transferred and resuspended to a 15 mL tube containing 10 mL 4 
°C BCM or TCM. 
 
2.4 Cell Culturing 
 
All cells cultured were kept 37°C, in a 7.5% CO2, 6,3% O2 in a humidified atmosphere and 
regularly split and/or washed depending on future experiments, cell viability and confluence. 
B-LCL are EBV-transformed and grew without external stimulation, the HPA-1a specific T-
cells however need to be stimulated to proliferate done by T-cell expansion of the culture. 
Cells were kept in culture flasks or culture plates fitting to the culture volume needed for 
specific goals. Cells were split when the pH drops below 7.2 pH (yellow culture medium), 
generally every 2 to 7 days. B-cells were cultured in BCM while T-cells were cultured in 
TCM, generally with added IL-2 (50U/mL) and if when T-cells looked less viable IL-15 
(5ng/mL). Cultures was washed after every 2-3 rounds of splitting to avoid build-up of 
cellular waist decreasing viability of the cells. Extreme care was taken to adhere to a high 







2.5 Expansion of Antigen-Specific T-cell lines 
 
To enumate clonal HPA-1a specific T-cells they have to be expanded by stimulation with 
appropriate antigen. Antigens that were used as stimulants for expansion were mainly PHA 
and anti-CD3 Ab but HPA-1a antigen could also be used. To prepare feeder cells, B-LCL 
cultures were started 1 week before and feeder cells were isolated by density gradient the day 
before and rested. B-LCL, T-cell and feeder cells all were counted on a haemocytometer and 
feeder cells were resuspended in TCM. Both feeder cells (B-LCL and PBMC’s) were 
radiated (16.000 rad). On a 24 wells plate the following was added per well; 2*105-5*105 T-
cells, B.LCL-cells 7,5*105 cells,  PBMC 3*106 cells and TCM containing cnti-CD3 Ab (30 
ng/mL of expansion culture) to a total volume of 2 mL. Generally between 1,5-3*106 T-cells 
can be obtained per well after expansion and an appropriate amount of well were expanded 
for future experiments. The expansion was incubated 37°C, in a 7.5% CO2 humidified 
atmosphere for 7-14 days depending on T-cells confluency following normal T-cell culture 
protocol. On the second day IL-2 (50 U/mL) and IL-15 (5ng/mL) to each expansion well. 
After expansion T-cells were washed or lymphopreped to remove the stimulant and dead cell 
debris. 
 
2.6 Density gradients 
 
2.6.1 PBMC and Red Blood Cell isolation from Buffy Coats 
 
For the isolation of PBMC’s and red blood cell (RBC) and also in the monocyte enrichment 
protocol the density gradient lymphoprep is used to separate cells depending on their density. 
With lymphoprep, 3 fractions can be obtained; from bottom to top RBC/polymorphonuclear 
cells, PBMC and plasma. Depending what is need one or both PBMC’s and RBC were 
isolated following this protocol.  
Here, mainly buffy coats (50 mL) were used and for monocyte enrichment smaller sample 
sizes were used. The samples were placed in an appropriate size tube (15,50 mL) and the 
samples were diluted with the same amount of PBS. The diluted sample was mixed by 




50 mL tube) The tubes are centrifuged for 20-30 minutes at 800 g with no brakes. The 
interphase (PBMC’s) is transferred to a new 15 mL tube. If RBC are isolated they can be 
pipetted in a similar manner to a separate tube after the interphase has been isolated. The 
isolated sample tubes are centrifuged at 250 g for 6 minutes washed with 10 mL 0,2% PBSA 
and supernatant decanted 3 times. The samples are resuspended in BCM after the last wash. 
The cells are then kept in the incubator until used at 37°C, in a 7.5% CO2, 6,3% O2 in a 
humidified atmosphere. 
 
2.6.2 Preparation of Platelet Rich Plasma 
 
Preparation of platelet rich plasma (PRP) is performed on either whole blood or buffy coats 
from an appropriate donor. Either Heparin or EDTA should be added to the culture medium 
to avoid coagulation of the platelets. If no anticoagulant can be used (the following protocol 
may not work with an anticoagulant) extreme care should be taken not to disturb or move the 
platelets too harshly or platelet activation may occur. A soft spin is performed on the sample 
for 15 minutes at 150 g. The yellow supernatant (top layer) is collected from the falcon tube 
and pipetted into a new 15 or 50 mL tube. The tube is centrifuged for 2 minutes a 200 g and 
again the supernatant is removed and place in a new tube. Then, a final spin is performed for 
10 minutes at 2000 g to pellet the platelets and the supernatant is decanted. The platelet pallet 
is resuspended in BCM or TCM depending on what it is used for in following protocols. 
Platelet rich plasma will from now on be written as platelets. 
 
2.6.3 Monocyte Enrichment 
 
Monocyte enrichment was performed to obtain monocytes used as APC’s in T-cells 
activation assays. For the enrichment of monocytes from PBMC’s the RosetteSepTM Human 
monocyte enrichment cocktail (Stemcell technologies) was used. The protocol provided by 
the manufacturer was followed with slight modifications. In short, 800 μL of RBC were 
isolated with lymphoprep (see PBMC and Red Blood Cell isolation from Buffy Coats). 
PBMC containing HLA-DRA/DRB3*01:01 MHC class II monocytes were thawed and rested 




mixed with the 0,8 mL of RBC as well as 100 µl ResetteSep Monocyte Enrichement cocktail. 
The mixture was incubated for 20 minutes at room temperature and then diluted with 2 mL of 
BCM before the 4 mL mixture was layered, carefully, on top of the lymphoprep. From here 
lymphoprep protocol was followed again and monocytes were washed 3 times with 0,2% 
PBSA (see PBMC and Red Blood Cell isolation from Buffy Coats). Enriched monocytes 
were  used for antigen pulsing. 
 
2.7 Flow cytometry and Fluorescent Staining of Cells and 
Platelets 
 
For this project,  the BD Fortessa at UiT Core Facilities was used either by manual loading of 
flow tubes or with a High-Throughput Screening (HTS) system in 96w format. PMT voltages 
were routinely calibrated with BD CS&T Beads, and the compensation set-up was calculated 
with single stained samples. Various protocols made use of flow cytometry analysis which 
were described in section in detail 2.8, 2.10.2, 2.11, 2.12 and 2.13. Fluorophore conjugated 
antibodies and their functions are shown in Table 3. 
Table 2 Complete list of the fluorophore conjugated antibodies used during this master thesis used in 
flow cytometry and CFSE. 
 





HPA-1a 26.4 – Alexafluor 
488 
In house \ 0,5 HPA antibodies 
specificity assay 
HPA-1a SZ-21 - FITC Bechman 
Coulter 
IM1758 1,6 HPA antibodies 
specificity assay 
HPA (human) Y2/51 - FITC Dako F0803 2,5 HPA antibodies 
specificity assay 
HPA (human) AP-3 – 
Alexafluor 488 




BD Pharmingen 554513 0,3 TNF-α assay 





Biolegend 300408 2 Proliferation assay 










Information about similarities and differences with regards to epitope reactivity in HPA-1a, 
HPA-1b and Rabbit Integrin was gathered by flow cytometry Here the following antibodies 
were used; AP3 (Alexa Fluor 488) and Y2/51 (FITC; Fluorescein isothiocyanate) are integrin 
β3-specific, 26.4 (Alexa Fluor 488) is HPA-1a-specific and Sz21 (FITC) is, in low 
concentration, shown to be HPA-1a-specific (33). The samples were gated for platelets on a 
double logarithmic scale and the Alexa Fluor 488 and FITC (emission maximum at 519 nm) 
fluorophores intensity were measured using the B detector (530/30 nm filter) on the blue (488 
nm) laser.  
To analyse the ability of B-LCL to load the L33 and lolP1 peptides a peptide-biotin + 
streptavidin-PE (emission maximum at 578 nm) setup was used and detected with the E 
detector (585/15 nm filter) on the YellowGreen (561 nm) laser. The samples were gated for 
B-LCL. 
To determine if and how much HPA-1a specific T-cell were activated by measure of 
proliferation, a TNF secretion and CFSE proliferation assay were performed. The TNF-α 
assay was performed using PE-mouse anti-human TNF-α (emission maximum at 578 nm) 
was used measuring intensity using the E detector (585/15 nm filter) on the YellowGreen 
(561 nm) laser. The samples were gated for CFSE+ T-cells and shown in a histogram with 
CFSE intensity on the x-axis and TNF-α (PE) expression of the y-axis. In the proliferation 
assay CFSE, CD3-PE (compensation), CD14-PE and CD4-PE-AlexaFluor 610 mAb 
conjugates were used. PE was detected as previously described and PE-AlexaFluor 610 
(emission maximum at 628 nm) intensity was measured using the YellowGreen (561 nm) 
laser on the D filter. First T-cells were gated in a FSC/SSC plot, this population was again 









2.8 Flowtest of platelet opsonization by integrin β3 specific 
antibodies. 
 
Human HPA-1aa, HPA-1bb and rabbit platelets were reacted with four different antibodies 
The examined antibodies will be; the anti-HPA-1a mAbs 26.4 (0.6 mg/mL, AF-488) and 
SZ21 (0.15 mg/mL, FITC), the anti-β3-integrin mAbs Y2/51 (0.1 mg/mL, FITC) and AP-3 (1 
mg/mL, AF-488).  
The antibodies were diluted in 0,2 % PBSA containing 2 mM EDTA at a concentration of 10 
μg/mL and.  25 μL per well in a 96 wells round bottom plate. 25 μL of platelet suspension 
was added to mixed by pipetting and incubated for 30 minutes on ice in the dark. TCM was 
added to the plate was centrifuged at 1900g for 5 minutes, fluid decanted and washed twice 
with 200 μL 0,2% PBSA/EDTA per well. After a final centrifugation and decanting of wash 
buffer a 100 μL of 0,2% PBSA/EDTA was added, and kept on ice until analysis. The samples 
were run on the flowcytometer and analyzed with FlowJoTM v7/8 (Becton Dickinson and 
Company, California). 
 
2.9 Carboxyfluorescein N-succinimidyl Ester (CFSE) Staining 
 
CFSE staining is the process where the non-fluorescent highly permeable carboxyfluorescein 
diacetate succinimidyl ester is enzymatically altered by the removal of two acetate groups 
(27). Hereafter the molecule can fluoresce and binds stably with cellular protein lysine 
residues (27). This technique was mainly used to stain T-cell over long periods of time for 
flow cytometry analysis and proliferation assays. CFSE is explained in more detail in the 
proliferation assay section. 
To be stained cell are spun down cells washed twice with PBS and the medium is discarded. 
The cell pellet is resuspended in 500 µl PBS. 10 µl 250 µg/ml CFSE dye is transferred to the 
resuspended cells (5 µM). The suspension mixed thoroughly and immediately transferred to 
37˚C water bath for 10 min. After the  of incubation 5 mL of ice cold IMDM 10% FBS 1% 
Pen/Strep is added and the cells are transferred to ice for 5 minutes. The cells are centrifuged 
4 min at 350 x g and washed with PBSA 3 times. 1-2 ml in IMDM + 10% FBS + 4% human 




7.5% CO2, 6,3% O2 in a humidified atmosphere to rest until used for experimentation. If the 
stained T-cells are kept for more than a few hours IL-2 is added in a concentration of 50 
U/mL. 
 
2.10 Antigen Pulsing of APC and T-cells 
 
The pulsing of APC including B-LCL and enriched monocytes from HLA-DRB3*01:01 
positive donors  was used in several different assays. Therefore the method used for pulsing 
various cells with various compounds is described here separately. And will in the 
experiments where they were used be referred to as for example “platelet derived HPA-1a 
pulsed monocytes”. All pulsing protocols below for APC are per well and yield enough cells 
to stimulate 1 well of T-cells on a 96 wells round bottom plate. An appropriate amount of 
wells should thus be prepared for the respective T-cell stimulation experiments. 
 
2.10.1 Peptide Pulsing of B-LCL 
 
Various peptide stock dilutions are used so the peptides were diluted to a concentration of 5 
µM peptide for appropriate loading. B-LCL were counted and resuspended 4*106/8 mL 
TCM, meaning every 100 µL contains 50.000 cells. An appropriate amount of wells with B-
LCL is prepared for the experiment in question (TNF-α, peptide loading assay or 
proliferation assay) and for each peptide to be loaded. B-LCL with L33, lolP1 and no peptide 
were prepared.  
Adamantane ethanol mix was made by mixing 0,25 µL [100mM] AdEtOH + 0,75 µL DMSO 
+ 9 µL TCM multiplied by the amount of wells (200 µL volume) + some extra. 10 µL of 
Adamantane mix was added to each well and acted as an MHC II loading enhancer. Each 
well thus contains 100 µL B-cells were added + 10 µL AdEtOH mix + 90 µL peptide. The 
round bottom plates were incubated for 4 hours at 37°C, in a 7.5% CO2, 6,3% O2 in a 
humidified atmosphere. All well were centrifuged in RotinaFuge 420R at 2100 rpm for 4 
min, supernatant decanted and resuspended in TCM. The pulsed B-LCL can now be used in 




To determine if the B-LCL used were viable and able peptide loaders a peptide loading assay 
can be performed as described below. This method uses the biotin – streptavidin binding to 
measure how much and if at all B-LCL can bind peptide in their MHC II molecules. 
Streptavidin is bound to a fluorophore and can be analysed by flow cytometry. 
The pulsing of the B-LCL is performed as described above with similar peptides, as there 
may be interpeptide differences. The peptides used during the assay will have conjugated 
biotin. 5 µM of peptide was added to each sample. After 4 hour incubation the plate was 
centrifuged on the RotinaFuge 420R at 2100 rpm for 4 min. The supernatant was decanted 
and 200 µL PBSA/Azide to each well, centrifuged and supernatant decanted. A 10 µL 
Streptavidin – PE + 390 µL PBSA/Azide (0,5 + 19,5) was made and 20 µL Streptavidin – PE 
dilution was added to each well. The plate was tapped to mix thoroughly and incubated for 15 
minutes on ice in the dark. 160 µL PBSA/Azide was added and the plate was thereafter 
centrifuged and supernatant decanted. 200 µL PBSA/Azide was added and all samples were 
resuspended. All samples were transferred to FACS tubes or inserted plate into the plate 
reader and analysed in the flowcytometer. 
 
2.10.2 Protein Pulsing of Monocytes with 26.4 linked Dynabeads 
 
26.4 linked Dynabeads were fashioned using the Dynabeads antibody coupling kit (Novex, 
life technologies), Dynabeads M-270 Epoxy (Novex, life technologies) and the 26.4 
monoclonal antibody from in house production. The protocol was adapted from Dynabeads® 
Antibody Coupling Kit Catalog number 14311D Revision Date June 2012 (Rev. 001) from 
Novex. The recommended amount of antibody was used for optimal coupling (5-10 µg/mg of 
26.4) and not optimal the amount for optimal binding capacity (20-30 µg/mg). 5 mg of beads 
(6,7*107 beads/mL) was coupled with 26.4 following the appropriate steps in the protocol for 
that amount. The antibody coupling takes two days. 
On the same day the 26.4 linked Dynabeads were incubated with ligand, platelet rich plasma 
was prepared (Section 2.6.2) or previously stored platelets from donors were thawed from 
cryo-storage. Extreme care was taken not to cause aggregation of platelets during this process 
as it is unknown what effect this has on HPA-1a molecules in this assay. HPA-1a+ platelets 




incubating for 1 hour at room temperature. Then, the lysates were centrifuged at 15000-
17000 g (highest available) for 45 minutes after which the supernatants were obtained and 
added to ~1 mg of 26.4 linked Dynabeads for each lysate type and incubated overnight at 4 
°C in a rotator.  
On day 3 the 26.4 linked Dynabeads with either rabbit integrin or HPA-1a bound or empty 
26.4 Dynabeads were incubated with the previously enriched monocytes. The overnight 
incubated beads were washed twice with help of a magnet using the washing buffer from the 
Dynabeads antibody coupling kit (Novex, life technologies). 0,1-1x106 beads bound with 
either integrin variant are pipetted from the respective tubes and resuspended in TCM (100 
µL) and 5x104 monocytes in TCM (100 µL) are mixed together and incubated overnight 
37°C, in a 7.5% CO2, 6,3% O2 in a humidified atmosphere.  
On day 4 the Dynabeads pulsed monocytes are centrifuged at 400 g for 4 minutes, 100 µL 
TCM was removed and the remaining 100 µL can be used in TNF- α or proliferation assay 
for T-cell activation. 
To assess the amount of 26.4 and integrin β3 protein (HPA-1a and rabbit integrin) bound to 
the beads, antibodies with conjugated reporters can be used to detect the integrin bound in the 
26.4. The SZ21 mAb (1:1000 from a 0,2 mg/mL stock) was used as the detecting antibody 
with Goat anti-rabbit IgG-HRP as secondary Ab for western blot. Of all variant of beads 
2x106 beads were taken and standard western blot protocol was followed (see section 2.13.6) 
with the above mentioned antibodies. The protocol was adapted from a protocol by Gøril 
Heide from an currently unpublished article. 
 
2.10.3 Platelet Derived Antigen Pulsing of Monocytes 
 
HPA-1a+ platelets, HPA-1b+ platelets and rabbit platelets were washed and counted on a 
haemocytometer and checked for viability on the microscope. Each platelets variant was 
incubated with the previously enriched monocytes. 0,1-1x106 platelets of the respective 
variants are pipetted from the respective tubes and resuspended in TCM (100 µL) and 5x104 
monocytes in TCM (100 µL) are mixed together and incubated in a 96 wells round bottom 





2.11 TNF-α Secretion Assay 
 
To measure the of activation of T-cells a TNF-α secretion assay done. T-cells were activated 
using either antigens derived from peptide, protein antigens bound on beads or whole platelet 
(see Table 1). lolP1 peptide was used as a control utilizing lolP1’s ability to stably bind in the 
HLA-DRB3*01:01 binding pocket without activating the HPA-1a specific T-cells (21, 37).  
APC cells (HLA-DRB3*01:01+ B-LCL or HLA-DRB3*01:01+ monocytes) were incubated 
with antigen (see 2.10) for 4 hours with adamantane ethanol (AdEtOH) if HLA-
DRB3*01:01+ B-LCL were pulsed or overnight if the pulsed APC’s were HLA-
DRB3*01:01+ monocytes. Previously expanded HPA-1a specific T-cells are washed or 
lymphopreped and CFSE stained (see 2.9) and rested overnight with IL-2 in an incubator at 
37°C, in a 7.5% CO2, 6,3% O2 in a humidified atmosphere. The following day the CFSE 
stained T-cells were counted and washed once with 0,2% PBSA. CFSE stained T-cells were 
resuspended in TCM without IL-2 or IL-15 at a 5-10*105 T-cells/ml concentration. The ratio 
of APC to T-cells was around 1:2-5. All B-LCL (D4BL4) and monocytes pulsed with various 
platelets protein or peptide types are counted, washed and resuspended at a concentration of 
1-5*106 APC/ml in TCM. 50 µL of CFSE HPA-1a specific CFSE stained T-cells and 50 µL 
are added per well on a 96 wells round bottom plate. A anti-TNF- α /TAPI-0 mix was made 
containing 0,2 µL TAPI-0/well (Enzo 1mM, cat.no: BML-PI133-0001), 0,3 µL/well PE 
mouse anti-human TNF- α (BD bioscience 0,2 mg/mL cat.no: 554513) and 4,5 µL/well TCM 
for a total of 5 µL/well. 5 µL of anti-TNF- α /TAPI-0 mix was added per well to all samples 
and controls. The plates were incubated for 4 hours at 37°C, in a 7.5% CO2, 6,3% O2 in a 
humidified atmosphere. After the 4 hours of incubation the samples were resuspended, 









2.12   Proliferation Assay 
 
The proliferation assay is the second assay type used in this study as a way to examine the T-
cells stimulating ability of certain peptides, proteins and platelet types. As before mentioned 
they can not only be used to determine if activation of T-cells is present but also the amount 
of activation and the percentage of population that has been activated.  
T-cells clone (D8T104) were examined and the response was assessed in a proliferation assay 
performed as discribed by M.T. Ahlen et.al. (38). T-cells were stimulated by means of 
peptide antigens, protein antigens bound on beads or whole platelet derived antigens (see 
Table 1).  
The preparation for the proliferation assay started one day before the assay start APC cells 
(HLA-DRB3*01:01+ B-LCL or HLA-DRB3*01:01+ monocytes) were incubated with antigen 
(see 2.10) for 4 hours with adamantane ethanol (AdEtOH) if HLA-DRB3*01:01+ B-LCL 
were pulsed or overnight if the pulsed APC’s were HLA-DRB3*01:01+ monocytes. Ready 
expanded HPA-1a specific T-cells, washed or lymphopreped to stop the expansion of the 
cells, were CFSE stained (see 2.9) and rested overnight with IL-2 in an incubator at 37°C, in 
a 7.5% CO2, 6,3% O2 in a humidified atmosphere. The CFSE stained T-cells and pulsed B-
LCL (D4BL4) and monocytes were prepared and placed in their respective wells at the same 
ratios as in the TNF-α secretion assay. The round bottom plates were incubated for 6-7 days 
at 37°C, in a 7.5% CO2, 6,3% O2 in a humidified atmosphere. The next day (day 1) 100 
µL/well of new medium containing 100 U/mL IL-2 and optionally 10 ng/mL IL-15 was 
added so that the concentration in each well will be 50 U/mL IL-2 and if used 5 ng/mL IL-15. 
New medium containing 50 U/mL IL-2 and if used 5 ng/mL IL-15 was provided to the 
samples as necessary when medium started turning orange. When T-cell confluency was 
determined to be appropriately high, the samples were resuspended, incubated for 20 minutes 
on ice with anti CD4/anti CD14 in the dark. After incubated samples were washed twice with 






2.13 Protein Isolation 
2.13.1 Size-Exclusion column preparation (Sephadex G50) 
 
Sephadex G-50 Superfine is a well-established gel filtration resin for desalting and buffer 
exchange of biomolecules >30 kDa. Here we use the resin as a prefilter to separate all 
molecules over 30 kDa from all molecules that are below that molecular weight. Hereby 
being able to use more pure samples affinity column.  
The current protocol was based on the Size Exclusion Chromatography Principles and 
Methods from GE healthcare and instructions disposable plastic columns by Thermo 
scientific and in short the following was performed. The swelling process was accelerated by 
using a water bath at 90°C for 1 hour serving simultaneously to degas the suspension. The 
rehydrated suspension was allowed to cool before use washed with 5-10 column volumes 
(CV) on a sintered glass filter and resuspended in 1 CV of milliQ water. The resin was 
washed with 20% ethanol storage solution and moved to a column with porous disc in the 
bottom, sealing the column with a porous disc over the resin. The pre-filtration column was 
filled with ~10 mL or 10 cm of resin and ran using gravity. Fractions were collected in 0,5-1 
mL samples and analysed for protein concentration using nanodrop. 
 
2.13.2 Affinity filtration column preparation   
 (Sepharose 4B CNBr-activated) 
 
CNBr- activated Sepharose 4B is a resin that can be chemically linked to molecules 
containing an amine. The molecules used for the preparation of the affinity column used in 
this study was mAb 26.4, which is highly specific for HPA-1a and presumably rabbit 
integrin.  
The current protocol was based on and adjusted from; Affinity Chromatography Vol. 3: 
Specific Groups of Biomolecules, GE Healthcare, 2014 and Methods from GE healthcare and 
instructions disposable plastic columns by Thermo scientific and , in short, performed as 
follows. An appropriate amount of freeze dried sepharose 4b CNBr-activated (1 gram for 2,5-




and rehydration buffer), 0,2 M NaHCO3 0,5 M NaCl - pH 9.1 (coupling buffer), 0,1 M Tris-
HCl – pH 8 (blocking buffer), 0,1 M acetate buffer 0,5 M NaCl – pH 4 (washing buffer low 
pH), 0,1 M Tris-HCl 0,5M NaCl – pH 8 (washing buffer high pH), 0,02% Sodium Azide 
(storage solution). The sepharose powder was rehydrated and washed with 200 mL washing 
buffer in small aliquots on a sintered glass filter. The rehydrated resin is collected and 
resuspended in coupling buffer + 26.4 mAb (2-5 mg mAb per mL resin) was added in 1:2 
(v/v) ratio and incubated for 1-2 hours and room temperature. The mAb solution was kept for 
nanodrop analysis of 26.4 binding to the resin beads. The resin was washed with 5 resin 
volumes of washing buffer and then incubated for 1 hour in blocking buffer, blocking any 
remaining active groups. The final washing step is 3 cycles of high and low pH washing 
buffer after which the resin is place into a fitting column as done in the sephadex G50 
protocol and can be store in storage buffer at 4 °C. 
 
2.13.3 Purification of human HPA-1a or Rabbit Integrin β3 antigen. 
 
The protocol for purification of HPA-1a or rabbit integrin was based on the method used by 
T. Bakchoul, O. Meyer et.al. and adjusted to fit the current study (40). A prefiltration size 
exclusion column with Sephadex G50 for removal of all molecules under 30 kDa and 
sequentially an 26.4 mAb linked affinity column to purify and isolate the integrin in question 
from the pre-filtered fractions. 
The following buffers were made. Lysis buffer consists of 0,1% Triton X-100 20 mmol/L 
Tris 150 mmol/L NaCl 100 µL/L protease inhibitor pH 7.4 (Roche, cOmplete, Mini, EDTA-
free). Three washing buffers were made for washing the column in high and low salt 
concentration once the protein solution has been run through the affinity column. Washing 
buffer 1 made from 50 mmol/L Tris 5 mmol/L NaCl 0,1% Triton X-100 - pH 8, washing 
buffer 2 consisting of 100 mmol/L Tris 500 mmol/L NaCl 0,1% Triton X-100 - pH 8 and 
washing buffer 3 is a solution containing 50 mmol/L Tris 5 mmol/L NaCl - pH 8. Elution 
buffer contains 100 mmol/L trisodium citrate dehydrate – pH 2. And finally the catching 
buffer which consists of 1 mol/L Tris-HCl – pH 9,5 to neutralize the elution buffer and 
prevent protein loss after elution. All buffers are degassed before use in the columns to 
maintain high efficiency of the columns. Hereafter these buffers will only be mentioned in 




HPA-1a or rabbit integrin platelets were washed three times and pelleted, being cautious not 
to activate the platelets in the process (Section 2.6.2). The obtained platelet pallet was 
resuspended in lysis buffer and incubated for 1 hour at 4 °C. The platelet lysate was 
centrifuged at 17.000 g (or the highest possible) for 45 minutes at 4 °C. The pre-filter column 
was made ready by washing the column with degassed MilliQ water (20% ethanol maybe 
added) and equilibrating the column with the lysis buffer. The lysis supernatant was then run 
through the pre-filter column and collected in fractions from the moment platelet lysate was 
added until the total volume run volume is sample volume +1 or 2 extra column volumes 
with lysis buffer (0,5-1ml per fraction). The pre-filtration column was washed with MilliQ 
water with 0,02% NaN3. The collected fractions were analysed on the nanodrop to determine 
the fraction with protein of interest. The affinity column was washed with each 2 column 
volumes of washing buffer 1,2 and 3 after which the column was equilibrated with 4-5 
column volumes of lysis buffer without TRITON X-100. The fractions containing the 
proteins of sizes 30 kDa and above were run on the affinity column + 1-2 column volumes of 
lysis buffer without TRITON X-100 to keep the column wet while the last of the sample 
volume runs on the column. The column was washed sequentially with 10 ml of washing 
buffer 1,2 and 3. The sample and wash run through were both collected in 1ml fraction. The 
column is eluted with 5 mL elution buffer (~0,5 mL/fraction) which is collected in fraction 
tubes containing each 0,5 mL of catching buffer for suspension neutralization. These 
fractions were then analysed by nanodrop, SDS-PAGE or western blot depending on what 
sensitivity level was required. Once the fraction with target protein have been determined, the 
target fraction were dialysed and concentrated using the Amicon ultracel 50k 15 ml. The 




The protocol for nanodrop analysis was done as instructed by the manufacturer using the 
A280 absorption measurement option on the Nanodrop One/One (NanoDrop Micro-UV/Vis 







SDS-PAGE was used to verify the purified fractions from the affinity column under reducing 
conditions. Reagents for SDS-PAGE were purchased from Invitrogen by Life Technologies. 
10 μL samples were taken from affinity column fractions to a Eppendorf tube containing 3.8 
μL NuPAGE 4x LDS Sample Buffer and 1.5 μL NuPAGE 10x Sample Reducing Agent. The 
samples were incubated on a heat block at 70 °C for 10 minutes. 600 mL of 1x NuPAGE 
Running buffer was made by diluting 30 mL of 20x NuPAGE Running Buffer in 570 mL 
MilliQ water. A NuPAGE® Novex® 4-12% Bis-Tris Gels, 1.5 mm 15 well gel was rinsed 
with water thoroughly on the outside and in the wells with a syringe. The gel was inserted in 
the inner chamber, the chamber was filled with 1x Running buffer. The outer chamber was 
filled with the remaining 1x Running buffer and 500 μL antioxidant was added to the inner 
chamber. 7 μL of each ladder, Novex Sharp Pre-stained and Unstained Protein Standard as 
well as 12 μL of each prepared sample was loaded to the gel. The gel is run for 35 minutes on 
200 V using the programmed settings on XCell SureLock Mini-Cell by Invitrogen, Life 
Technologies.  
The gel was washed with deionized water heated close to boiling and placing the gel on an 
orbital shaker for 1 minute, discarding the water afterwards. This washing step was repeated 
3 times and there after stained for 20 minutes on a shaker with 20 mL SimplyBlue SafeStain 
also heated close to boiling. The gel was then washed with 100 mL of deionized water on a 
shaker for 10 minutes before 20 mL of 20% NaCl was supplied. The gel left on the shaker 
overnight and analyzed the following day. 
 
2.13.6 Western Blot 
 
Western blot is a method for the detection of specific protein in a sample by the binding of 
protein-specific antibodies. The western blotting is performed on the developed SDS-PAGE 
gel from which the proteins are transferred to a nitrocellulose membrane by electroblotting. 
The detection of protein is done by specific antibodies conjugated with colorimetric, 
chemiluminescent or fluorescent reporter molecules (41). Here the chemiluminescent method 




SDS-PAGE under reduced condition was performed as described in section 2.13.5, however 
the unstained ladder was changed to MagicMark XP Western Protein Standard (Invitrogen by 
Life Technologies) and of both ladders only 1 μL was loaded into the respective wells. 
A membrane, Invitrolon PVDF Filter Paper Sandwich 0.45 um Pore Size (Invitrogen by Life 
Technologies) was prepared by saturating the membrane first in 100 % methanol for 3 
seconds, secondly in deionized water for 10 seconds and finally 5 minutes in 1x Transfer 
Buffer diluted from NuPAGE 20x Transfer Buffer (Invitrogen by Life Technologies). The 
plastic shell and wells from the developed SDS-PAGE gel were removed and the membrane 
was place on top of the gel. Filter papers were placed on top and bottom of the membrane and 
gel construction and then sandwiched between 1x Transfer Buffer moistened sponges. This 
sandwich was then positioned in the blotting apparatus with 1x Transfer Buffer filling the 
inner chamber and water in the outer chamber. The gel was electroblotted for 1 hour at 25 V 
using the pre-programmed settings on XCell SureLock Mini-Cell by Invitrogen, Life 
Technologies. 
The membrane was washed three times in PBS 0,05% Tween 20 for 10-15 minutes. While 
the membrane is incubated for 1 hour in blocking reagent (0.2 % goat IgG; Thermo 
Scientific, Waltham, Massachusetts to SuperBlock (PBS) Blocking Buffer (Thermo 
Scientific) and 0.05 % Tween 20) human anti-ITGB3 antibody (26.4) was diluted 1:1000 in 
Blocking Buffer supplied with 0.05 % Tween 20 to 0,2 μg/mL. Once blocking had finished 
the membrane was incubated overnight in primary antibody solution at 4 ° C with minimal 
rotation. 
The next day, the membrane was washed three times in PBS 0.05% Tween 20 for 10-15 
minutes with gentle shaking. Polyclonal goat anti-mouse IgG (HRP) (Sigma-Aldrich) was 
diluted 1/10000 in blocking buffer with 0.05 % Tween 20, 1 µl to 10 ml and incubate for 1 
hour gently shaking. Again, the membrane was washed three times after which the substrate 
solution was made by mixing SuperSignal West Femto Maximum Sensitivity Substrate 
(Thermo Scientific) components 1: 1 and pipetting 2 mL onto the membrane. The membrane 
was incubated for 5 minutes in darkness and then photographed using ImageQuant LAS 4000 







3.1 Rabbit and human integrin β3 amino acid sequences are 
similar at residues known to form the HPA-1a epitope 
except for valine at residue 33. 
 
To examine the differences and similarities between the 25-33, 39 and 470 amino acid 
positions in Integrin β3 in various animals, a search was performed on ensemble.org. The 
current list includes only a few animals, but care was taken to include animals which are 
more available for research purposes and for collection of sufficient quantities of blood for 
potential therapy. The comparison is made to show what animals could be potential sources 
of integrin β3 protein similar enough to HPA-1a Integrin β3 to potentially activate the HPA-
1a specific T-cells. 
Our T-cell clones specific for HPA-1a integrin β3 are specific for the 25-33(L33) amino acid 
sequence of the integrin β3. This 25-33 amino acid sequence is presented in the 
DRA/DRB3*01:01 MHC II on APC like monocytes or B-LCL to which the T-cell clones can 
bind and get potentially activated. The DRB3*01:01 has 3 main anchor pockets P1, P4 and 
P9 and one less important anchor pocket P6 (22, 37). P9 is of specific importance to our 
research as it is the binding site of the amino acid at position 33, where the L33P mutation 
from HPA-1a to HPA-1b is found. The amino acid sequence 25-33 of the integrin β3 with the 
relevant anchor pockets is shown in table 1. Specifically human HPA-1c and rabbit integrin 
are identical. Also the L33V difference from HPA-1a to HPA-1c/rabbit integrin β3 is 
important as Leucine and Valine are both small hydrophobic amino acid and may bind 
equally strong in the hydrophobic anchor pocket P9 (4, 8, 34). Multiple other animals are 
shown, having 1 or more mutations with non- similar amino acids. 
Additionally is the binding site of 26.4 mAb shown in table 1, being amino acid position 30, 
32, 33, 39, 470 also called APLDQ (from the HPA-1a integrin β3 amino acid sequence), 
however other amino acid in between positions 33 and 470 may also be important in 26.4 
binding (34). Again here the characteristics of the amino acids play an important role and 
similar amino acids can be found in HPA-1a, HPA-1c and rabbit integrin (APLDQ or 
APVDQ) but not in the other animals shown. Although several species of wild animals (e.g. 




would for practical or esthetical reasons arguably not be suitable as donors of blood for 
therapeutic purposes. Among common household animals, only the rabbit has a sequence that 
could potentially mimic the HPA-1a  epitope. 
 
3.2  Anti-HPA-1a antibodies bind rabbit platelets 
 
Various types of platelets from HPA-1aa+, HPA-1bb+ human and rabbit donors were 
analysed to specify their binding capacity for Y2/51, SZ21, 26.4 and AP3 mAb’s.  
The cryostored samples were taken at earlier point in time then fresh or preserved platelet 
samples as well as at different FITC/AlexaFluor 488 detector voltages. Negative will be 
classified as all MFI lower than 50, slightly positive for MFI between 51-1000 and all above 
1001 MFI will be positive. The cryopreserved samples showed the following results (Fig 4-
1). HPA-1a platelets where positive for SZ21, 26.4, AP3 and Y2/51 and negative for the no 
mAB control. HPA-1b platelets where positive for AP3 and Y2/51, only slightly positive for 
SZ21  and negative for the 26.4 mAb and no mAB control. Rabbit platelets where positive 
for SZ21, 26.4 and negative for no mAb, Y2/51  and AP3. Fresh and preserved platelets 
controls showed similar results to their respective partners (Fig 4-1). Thus, rabbit platelets are 
bound by HPA-1a-specific monoclonal antibodies. 









Figure 3-1 Binding of various anti-human integrin β3 antibodies to HPA-1a, HPA-1b and rabbit platelets fresh, preserved or cryopreserved. 
The various platelets were incubated with Y2/51, SZ21, 26.4, AP3 or without conjugated with FITC or AlexaFluor 488. human β3 integrin can 
be bound by AP3 and Y2/51, while 26.4 and SZ21 are specific for the HPA-1a variant of β3 integrin. The mean fluorescence intensity (MFI) is 





3.3 Monocytes, PBMC’s and B-LCL’s were analysed and 
prepared for proliferation assay. 
 
Various control steps were taken and performed to ascertain the significance of the final 
results. Adamantane ethanol (AdEtOH), a known enhancer of peptide-binding to MHC class 
II molecules, was assessed for improved antigen-presentation to T cells by peptide-pulsed B-
LCL (See Appendix II). Also density gradient monocyte enrichment was analysed and T-cell 
CFSE staining quantified. Finally, the binding of 26.4 mAb on Dynabeads and consequently 
the binding of either HPA-1a or rabbit integrin was quantified by western blot. 
 
3.3.1 B-LCL D4BL4’s ability to present L33 and LolP1 peptides was 
verified. 
 
To analyse whether AdEtOH could enhance the capability of our B-LCL clone D4BL4 to 
present L33 and LolP1 peptides, binding of biotin-labelled peptides (L33-biotin and LolP1-
biotin) to D4BL4 cells was assess using streptavidin conjugated with PE. This method allows 
for a quantification of the surface presentation of the respective peptides. Both L33 and 
LolP1 were tested with or without AdEtOH as an MHC II loading enhancer, as well as 
control with no peptide and only biotin without peptide bound also with and without AdEtOH 
(control of AdEtOH improved binding in appendix II-II). Quantification of peptide binding in 
MHC II was measured in MFI by flow cytometry.  
Results showed that L33-biotin binding to B-LCL with AdEtOH was highest with a MFI of 
508, likely binding the DRB3*01:01-peptide complex. LolP1-biotin binding was measured at 
a MFI of 370,5 with AdEtOH. L33-biotin and LolP1-biotin without added AdEtOH had a 
measured MFI of respectively 190,7 and 135,3. The no peptide and only biotin control with 
added AdEtOH showed a MFI of respectively 120,1 and 138,3 of unspecific streptavidin or 
biotin binding in MHC II. Without AdEtOH the no peptide and biotin control showed a 
unspecific binding quantification of 74,3 MFI for the no peptide control and 94,6 MFI for 
only biotin binding (Fig 4-2 A) In Fig 4-2 B the results can be seen summarized in a bar 
graph showing more accurately the individual differences of the peptide MHC II binding 
stability and quantitation. Our B-LCL cell line was thus shown to take up and present L33 





3.3.2 Monocytes could be significantly enriched in a PBMC population 
by the density gradient method. 
 
For the presentation of antigen via protein or whole platelets, monocytes were used as 
suitable APC for their ability to phagocytose and process larger antigens. PBMC’s were 
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Figure 3-2 quantification of B-LCL clone D4BL4’s MHC II binding ability to biotin-L33 and biotin-lolP1 using Adamantane 
Ethanol as a loading enhancer.  
The binding of L33-biotin and lolP1-biotin was quantified in the presence and absence of AdEtOH to determine if the clone was 
viable as an APC for proliferation studies. The B-LCLs were first incubated with the biotin-“peptide” or with just biotin or no 
peptide and variably adamantane ethanol. Then streptavidin-PE was added and the samples were measured by flow cytometry, 
shown in A with on the right the MFI. In B the MFI values are summarized to show the differences in MFI per sample more 




Thereafter, they were treated with RosetteSep monocyte enrichment cocktail and again 
treated with a density gradient.  
Gating for live cells and suspected monocytes is shown on the left, the live cells are then 
further analysed on PE intensity shown on the right (Fig 4-4). Non enriched PBMC generally 
had around 10,6% monocytes within the PBMC population. Monocytes enriched PBMC 
showed in large population in the suspected monocytes in the scatter plot on the left. Also in 
the PE intensity histogram increased monocyte count could be detected at 64,7%. Monocytes 
enrichment controls were performed before all proliferation experiments and figure 4-4 is a 
representation of the general result (other monocytes enrichments controls not shown). 
 
Figure 3-3 Monocyte enrichment control on non-enriched and enriched PBMC populations.  
On the left the scatter plot is represented and on the right a histogram of PE intensity from the mAb anti-CD14-PE binding 
monocytes is shown. The upper two figures represent the non-enriched PBMC population and the lower two figures show a 
monocyte enriched PBMC population. A suspected monocyte gate is shown in the scatter plots to visualize were monocytes 
are expected to appear. A live cell gate is shown excluding dead material, and is further analyzed in the histogram. Both 




3.3.3 CFSE staining of HPA-1a specific T-cells was quantified. 
 
The CFSE staining is an integral part of the proliferation assay and was therefore assessed by 
flow cytometry analysis. 1 day after staining D8T104 cells were validated for CFSE staining 
and the intensity of CFSE staining was monitored to determine where the parent population is 
expected to be in the proliferation experiments for a specific green channel detector voltage.  
Both non-stained and CFSE stained D8T104 cells were analysed before every proliferation 
assay to respectively determine the autofluorescence and CFSE staining intensity. The T-cell 
population was gated as shown in figure 4-5 for both stained and unstained D8T104. No 
significant changes in the T-cell population before and after staining could be detected. The 
non-CFSE stained D8T104 showed 98,2% T-cell population at autofluorescence intensities of 
around 2*102. A smaller T-cell population of 1,56% could be detected at an intensity close to 
105. The CFSE stained T-cells showed a population of 99,9% of the total population at a 
CFSE intensity of ~7*104 with a negligible 0,101% of the total population at auto fluorescent 
CFSE intensity (Fig 4-5). CFSE staining was thus successful and could reliably be used for 





Figure 3-4 CFSE staining control of T-cell clone D8T104.  
D8T104 was CFSE stained and then analyzed by flow cytometry measuring in the green FITC channel. CFSE stained T-cells 
(bottom) were compared to non-stained T-cells (top). On the left scatter plots show the gating for the T-cell population, 
which were in turn further analyzed in a histogram for CFSE intensity. The histogram shows a CFSE negative region where 
non-stained T-cells are suspected to be and a CFSE positive region were CFSE stained cell can be expected to appear. 
3.3.4 Dynabeads conjugated mAb 26.4 can bind HPA-1a and Rabbit 
integrin.  
 
A western blot analysis of the beads was performed firstly to determine if the Dynabeads had 
been conjugated with the in-house 26.4 mAb and secondly if in turn the 26.4 was able to bind 
rabbit or HPA-1a integrin. 1 µL and 10 µL of Dynabeads with only 26.4 mAb or 26.4 mAb 
conjugated Dynabeads incubated with rabbit or HPA-1a integrin were examined. The 26.4 




Several strong bands at 57 kDa, and weaker bands at 120 kDa, 80 kDa, 55 kDa, 48 kDa, 33 
kDa and 27 kDa were seen for the samples in western blot A (26.4 dynabeads with HPA-1a 
or rabbit integrin) (Fig 4-1A). The western blot B presented with faint bands at 50 kDa and 
25 kDa only in the beads 26.4 10 µL sample (Fig 4-1B), showing that mAb 26.4 was coupled 
to the beads. Thus, mAb 26.4-coupled beads precipitated several molecule from rabbit 
platelet lysate detectable by mAb SZ21. 
3.4 T-cell activation assays show HPA-1a specific T-cell 
activation by rabbit integrin β antigen. 
 
Shown below are the results from the TNF-α and proliferation assays. The T-cells were 
incubated with B-LCL or monocytes presenting HPA-1a, HPA-1bs, LolP1 or rabbit integrin 
antigenic peptides derived from peptides, protein or whole platelets. The activation was then 
A B 
Figure 3-5 Western blot of Dynabeads conjugated with 26.4 and incubated with either rabbit or HPA-1a 
integrin showed significant binding of the respective integrin types.  
Rabbit and HPA-1a integrin from respectively rabbit and human HPA-1aa+ donors platelets lysate was 
captured on 26.4 conjugated Dynabeads. The beads were analyzed under reducing conditions on a western 
blot. The western blot showed several strong bands at 57 kDa, and weaker bands at 120 kDa, 80 kDa, 55 
kDa, 48 kDa, 33 kDa and 27 kDa for the samples in blot A. The western blot B showed one band at 50 kDa 
and 25 kDa only in the beads 26.4 10 µL sample. For both western blot MagicMark XP western protein 




measured by the excretion of TNF-α in the TNF-α assay and by proliferation percentage of 
the total T-cell population in the proliferation assay. The TNF-α assay measured the 
activation after 4 hours and the proliferation after 5-7 days.  
 
3.4.1 TNF-α assays 
 
The TNF-α assays were done with one T-cell clone, D8T104, specific to HPA-1a. The TNF-α 
expression was measured by the inhibition of TACE by TAPI 0 after which the membrane 
bound TNF-α was bound by an anti-TNF-α PE mAb.  
A control for TNF-α expression was performed by measuring the T-cell clone for TNF-α 
expression without incubation of any APC. This blank control showed no TNF-α expression 
with 99,9% of T-cells being in the TNF-α- gate (Fig 4-7). The rest of the experiment is 
divided into 3 parts; platelet-pulsed monocytes, integrin β3-pulsed monocytes and peptide-
pulsed B-LCL. As a negative control for the platelet-pulsed monocyte T-cell clone incubation 
proliferation assay, the D8T104 presented with HPA-1b platelet antigen showed only a small 
population of 1,69% being TNF-α+. Rabbit platelet-pulsed monocytes activated 89,5% of the 
D8T104 population and HPA-1a+ platelet pulsed monocytes activated 90,5% of the D8T104 
population. In the protein-pulsed monocytes proliferation assay the proteins were bound on 
Dynabeads before-hand. An extra control here was incubating the D8T104 T-cells with 
Dynabeads pulsed monocytes, where 2,43% of the T-cell population was in the TNF-α+ gate. 
The rabbit integrin activated 4,75% of the D8T104 population and HPA-1a integrin activated 
29,8% of the D8T104 population. The final part was B-LCL pulsing with LolP1 and L33 
peptide as well as a B-LCL only control. The B-LCL control showed 0,92% of the D8T104 
population being activated, LolP1 activated 0,97% in the TNF-α+ gate and L33 had 58,1% of 
the D8T104 population being activated (Fig 4-7). The X-axis shows CFSE and the Y-axis 
showed TNF-α expression by PE. The TNF-α assay shows that rabbit integrin β3 antigen, in 




























Figure 3-6 TNF-α expression in D8T104 T-cell clones incubated with peptide, protein or whole platelet-pulsed APC’s. 
A TNF-α assay was performed on D8T104 T-cells incubated with various antigen pulsed APC. The following APC pulsed with antigen were 
used (top to bottom); A control with no APC. A platelet series with monocytes pulsed with HPA-1b+, HPA-1a+ and rabbit platelets. A protein 
(bound on Dynabeads) series with monocytes pulsed with only Dynabeads, Dynabeads bound rabbit integrin and Dynabeads bound HPA-1a 
integrin. And finally a peptide series with B-LCL non-pulsed, pulsed with LolP1 (negative control) and pulsed with L33 (HPA-1a-like 
peptide). On the X-axis CFSE intensity is shown with D8T104 CFSE stained, they end up on the right of the dot plots. On the Y-axis the PE 
intensity (TNF-α expression) is presented. A gate for TNF-α+ T-cells is shown in top right corners and in the lower right corner a TNF-α- 
gate. The percentages shown in the dot plots represent the ratios of the D8T104 populations expressing TNF-α or not. APC’s were not 




This assay was done in duplicate and for the orderliness of the results only one of the 
repetitions is shown for the flow cytometry results. The complete results are compiled in 













































































Peptide Protein Platelets Control
Figure 3-7 D8T104 T-cell clone activation measured in the percentage of the population excreting TNF-α measured by flow cytometry.  
The complete result from the TNF-α assay is compiled here in a graph with sample types on the X-axis and the percentage of the population that 
has started expressing TNF-α on the Y-axis. In orange the peptide series is shown, blue is for the protein series, purple for the platelet series and 




3.4.2 Proliferation assays 
 
A second method of measuring the activation of specific T-cells is the proliferation assay. 
The HPA-1a specific T-cell clones were presented via APC’s with various antigens and then 
measured for the percentage of the population having proliferated. The assay is described in 
detail in section 2.12, but in short; the T-cells were CFSE stained and if activated will start 
proliferation causing the CFSE intensity to half every division. This decrease can be made 
visible and measured by flow cytometry.  
As a preliminary test of the proliferation assay the setup was run with only platelets. A 
proliferation assay had been performed before by M.T. Ahlen et.al and was used to determine 
if it could be replicated in a similar sense (39). Here, the T-cell clone D8T104 was presented 
with platelet derived antigens from HPA-1a, HPA-1b and rabbit platelets as well as a control 
with no platelets. Monocytes were used for the presentation of platelet derived antigens. The 
results showed that 36,7% of the D8T104 population had proliferated by HPA-1a platelet 
derived antigen presentation. 10,8%, 38,5% and 15,1% activation of the D8T104 cells could 
be measured in respectively HPA-1b, rabbit and no platelet derived antigen presentation (Fig 
4-9). These results indicated that the assay is functional and ready to be used for a full 
antigen panel. 
 
Figure 3-8 D8T104 T-cell clone stimulated by various platelet derived antigens measured in the percentage of T-cell 
population that proliferated.  
The results from the preliminary proliferation assay are compiled here in a graph with sample types on the X-axis and the 
percentage of the population that has proliferated on the Y-axis. The samples shown her are HPA-1a+platelet-derived 
antigen presentation (HPA-1a), HPA-1b+platelet-derived antigen presentation (HPA-1b), rabbit platelet-derived antigen 



















The complete setup for the proliferation assay is shown below in figure 4-10, similarly 
divided as done in the TNF-α assay into a peptide, a protein on Dynabeads and platelet series. 
All proliferation histograms have been analysed with FlowJo software using the proliferation 
function providing an overlay showing in red the parent population and in pink the daughter 
populations (1 daughter population per peak). Two controls were performed, a non-CFSE 
stained T-cell control at a 105 CFSE (FITC) intensity signifying the T-cell population after 
having lost all fluorescence (about 8 divisions) (Fig 4-10 top left). The second control shows 
non-stimulated CFSE-stained D8T104, to show where the population is at full CFSE intensity 
as well as the amount of non-specific activation to be expected (Fig 4-10 top right). Here, the 
CFSE intensity was at 50.000 were about 1,9% of the population had started proliferating. 
The peptide series shows D8T104 responding to LolP1 (negative control), L33 and a control 
with non-pulsed B-LCL’s. The no peptide (non-pulsed B-LCL) control showed a 0,1% 
portion of the original HPA-1a specific T-cell population having proliferated. The LolP1 and 
L33 stimulated D8T104 population respectively show a 0,4% and 37,8% of the CFSE stained 
D8T104 population proliferating. In the L33 peptide-pulsed B-LCL incubated with D8T104 a 
histogram with at least 3 individual peaks can be seen representing a non-dividing parent and 
two dividing daughter populations. The protein of Dynabeads series had one control with 
only 26.4 Dynabeads -pulsed monocytes (no protein), a rabbit integrin bound on 26.4 
Dynabeads and HPA-1a integrin bound on 26.4 Dynabeads, all incubated with monocytes as 
APC before culture with D8T104 cells. The no protein control showed 9,4% of the T-cell 
population proliferating and the rabbit integrin and HPA-1a integrin samples 8,0 and 16% 
show of the T-cell population proliferating. Individual peaks are harder to recognize in these 
samples, but all three have up to 6 visible peaks. The final series were samples where 
monocytes pulsed with HPA-1b, rabbit or HPA-1a+ platelets were incubated with D8T104. 
The D8T104 T-cells showed respectively 5,9%, 94,6% and 99,5% of the D8T104 population 
proliferating (Fig 4-10). Proliferation results showed that rabbit platelet antigen was able to 
stimulate HPA-1a specific T-cell to be activated and proliferate, but it could not conclusively 


























Figure 3-9 Proliferation measure as a percentage of the parent population of D8T104 T-cell clone incubated with peptide, protein or whole platelet-
pulsed APC’s.  
A proliferation assay was performed on D8T104 T-cells incubated with various antigen pulsed APC. The following APC pulsed with antigen were used (top 
to bottom); A control with unstained and CFSE stained D8T104, both without APC. A peptide series with B-LCL non-pulsed, pulsed with LolP1 (negative 
control) and pulsed with L33 (HPA-1a-like peptide). A protein (bound on Dynabeads) series with monocytes pulsed with only Dynabeads, Dynabeads 
bound rabbit integrin and Dynabeads bound HPA-1a integrin. And finally a platelet series with monocytes pulsed with HPA-1b+, HPA-1a+ and rabbit 
platelets. On the X-axis CFSE intensity is shown with D8T104 CFSE stained showing on the right of the dot plots and moving to the left when dividing a 
halving CFSE intensity. On the Y-axis the count is presented. The histograms have an overlay showing the parent population (non-dividing T-cells) in red 





Also this proliferation assay was done in duplicate and to represent the results in an 
understandable manner the results of only one of the repetitions is shown for the flow 
cytometry results. The complete results are compiled in figure 4-11 where the percentage of 
the D8T104 population that has proliferated is shown. 
 
Figure 3-10 D8T104 T-cell clone activation measured in the percentage of the population having proliferated measured 
by flow cytometry. 
The complete results from the proliferation assay is compiled here in a graph with sample types on the X-axis and the 
percentage of the population that has proliferated compared to the original population on the Y-axis. In orange the peptide 
series is shown, blue is for the protein bound on Dynabeads series, purple for the platelet series and red for the controls. No 
mono(cyte) 1b protein stimulation was performed in this panel. 
 
3.5 HPA-1a and rabbit integrin protein purification results  
 
In this result section the isolation and purification results on rabbit and HPA-1a integrin β3 
are presented. Two controls where performed respectively measuring that the effectivity and 












































mAb 26.4. Finally, a preliminary test of the complete purification setup (pre-filter and 
affinity column) was tested with a small sample of rabbit platelet lysate. 
 
3.5.1 Molecules > 30 kDa could be isolated with the prefiltration column. 
 
A sephadex G50 prefiltration column was made to filtrate out all molecules smaller than 30 
kDa from the rabbit and human HPA-1a+ platelet lysate. The prefiltration of the platelet 
lysates was performed to add a more refined sample on the valuable 26.4 mAb affinity 
column.  
The column was tested with bovine albumin (65 kDa) to determine the void volume and in 
which fractions the integrin molecules could be expected to be. Protein concentration was 
measured by A280 absorption by Nanodrop One/One. The albumin showed an increased 
concentration of protein in fractions 2,5 to 4 (0,5 mL per fraction) and two lesser increase in 
protein concentration in fraction 10 and 11,5. The filtrated rabbit platelet lysate showed 
increase in concentration from fractions 2 to 5 (1 mL per fraction ) and a second increase 
from fraction 6 to 8 with a slow decrease in concentration towards fraction 13 (Fig 4-12). It 
could be concluded that larger proteins exited the column after 2 mL (2 fractions) of void 
volume up to 6 mL (fraction 6), as albumin coincides with this top and therefor it may be 





Figure 3-11 A280 absorption measurement of filtered fraction from pre-filter column by Nanodrop of Albumin and rabbit 
platelet lysate.  
The control protein albumin was filtered through the pre-filter column and plotted for A280 absorption per 0,5 mL fraction. 
Rabbit platelets lysate was filtered and measured by A280 absorption per 1 mL fraction. Both measurements were plotted in 
a graph with A280 absorption on Y-axis and fraction number on the X-axis, visualizing protein concentration per fraction 
for the respective samples.  
 
3.5.2 26.4 mAb was found in the supernatant of boiled 26.4 mAb-linked 
CNBr Sepharose resin. 
 
A western blot was also performed on a small sample of 26.4 mAb-linked CNBr Sepharose 
resin. The resin was boiled to detach the 26.4 from the resin, centrifuge the sample and then 
determine if 26.4 mAb could be found in the supernatant.  
From left to right the following lanes can be seen; the magic mark XP molecular ladder, a 10 
µL sample volume of 26.4 mAb resin and a 1 µL of 26.4 mAb bound resin. Both sample 
lanes showed a band at about 58 kDa and 25 kDa, where the 10 µL sample volume of 26.4 































Figure 3-12 Western blot of boiled 26.4 mAb linked CNBr Sepharose resin.  
26.4 mAb linked CNBr sepharose resin was boiled to detach the mAb from the resin. 1 µL and 10 µL samples were taken 
from the supernatant and used for western blot sample preparation and run for analysis. The supernatant were analyzed 
under reducing conditions on a western blot. The western blot showed 2 strong bands at 58 kDa, and 2 strong bands at 25 
kDa for the samples. For both western blot MagicMark XP western protein standard were used. The primary antibody used 
was rabbit anti-human IgG and the secondary was anti-rabbit IgG HRP. 
 
3.5.3 No Rabbit and HPA-1a integrin could found in the elution fraction 
for HPA-1a integrin isolation.  
 
A final western blot was done on human and filtrated rabbit platelet lysate. Human platelets 
lysate at no dilution, 100x dilution and 10.000x dilution. Pre-filtrate fractions F2 to F4, the 
wash fraction (whole wash was collected in 1 fraction) and Elution fraction E8 to E10 and 
E14 + E15 were analysed. Human platelet lysate samples showed a continues band for the 
undiluted sample, while the 100x diluted sample showed several band at 75, 70, 58, 43, 25 
and 19 kDa. The 10.000x diluted human platelet lysate did not show any noticeable bands. 
Moving on to the pre-filtrated and affinity isolated fractions, several bands were found in the 
pre-filtrate fraction 3 and 4 at 125, 82, 75, 58 and 42 kDa. The darkest band is at 75 kDa. 
Also the Wash fraction showed a vague band at 75 kDa. No bands could be detected in the 




used for the size determination of the bands. Rabbit integrin β3 could be detected in the 





Filtrated Rabbit Platelet Lysate 
Figure 3-13 Western blot of human platelet lysate at various dilution states and various fraction of pre-filtrated or affinity purified rabbit 
platelet lysate.  
12 µL samples were taken from human and rabbit platelet lysate as depicted above. The lysate and purified fractions were analyzed under 
reducing conditions on a western blot. The western blot showed 1 continuous band for the human platelet lysate amd several fainter bands for 
the 100x diluted human platelet lysate. Strong bands at 75 kDa, and lighter bands at 75, 70, 58, 43, 25 and 19 kDa  for the pre-filtrate F3 and 
F4 samples were detected. 1 Faint band at 75 kDa was also found in the wash fraction, while no band could be found in the elution fractions. 





During this study the long term goal is to prevent the occurrence of FNAIT by the induction 
of oral tolerance against human platelet antigen, HPA-1a, in pregnant HPA-1bb women. To 
achieve this long term goal 3 primary objectives were set for this study. Firstly, to determine 
if HPA-1a specific antibodies can bind rabbit platelets. Secondly, examine whether rabbit 
platelets can activate HPA-1a specific T-cells. Finally, to examine whether HPA-1a specific 
T cells can specifically recognize and be activated by rabbit integrin β3 protein, rabbit 
integrin β3 therefor needs to be isolated.  
 
4.1 Rabbit integrin is, in theory, an activating antigen for HPA-
1a specific T-cells. 
 
In previous studies, it was proven that certain peptides with 1 amino acid substitution in the 
HPA-1a antigen L33 could still induce activation in HPA-1a specific T-cells (4). Specifically 
the V33 ( AWCSDEALPVGS) and I33 (AWCSDEALPIGS) peptides with respectively 
Valine and Isoleucine substituted at position 33 of the HPA-1a integrin β3 protein, were 
identified as equally effective activators (4). As previously explained, the DRB3*01:01 
consists of 3 main binding pockets P1, P4 and P9 with different characteristics determined by 
the make-up of the binding pockets amino acids (22). The recognition of rabbit platelet 
antigen by HPA-1a-specific T cells is likely due to efficient anchoring of rabbit V33 peptide, 
present in rabbit integrin β3, to the HLA-DRA/DRB3*01:01 MHC class II molecule (22); the 
valine residue will then be buried in the P9 pocket and the remaining residues within the T 
cell epitope will be similar to that of HPA-1a. Thus, the valine is likely not contacted directly 
by the TCR, but serves to anchor the peptide to the MHC molecule. 
Using rabbit blood products for treatment by oral tolerance induction would be more 
esthetical and culturally acceptable compared to using human or even animals such as apes, 
cats, dogs and bears, which all carry the HPA-1a T cell epitope. Also, some of these animals 
would probably be challenging to draw blood from. Obtaining HPA-1a like antigens from 
other sources, like rabbits, is be more ethical and manageable. Additionally, rabbit could be 





4.2 Binding of the 26.4 antibody to the rabbit platelets 
indicates HPA-1a specific T-cell may be specific to rabbit 
integrin β3.  
 
The antibody binding panel performed on human HPA-1a+, HPA-1b+ or rabbit+ platelets 
showed binding of human platelets as expected from previous studies (5, 31, 32, 34). Rabbit 
platelets were not bound by AP3 and Y2/51 as they are specific to human integrin β3 (31, 
32). Mabs 26.4 and SZ21 however were both able to bind the integrin β3 on rabbit platelets 
since they are both specific for HPA-1a defining epitope of integrin β3 (5, 34). When the 
binding of mAb 26.4 to rabbit and HPA-1a integrin are compared, the binding of 26.4 does 
show to be less in rabbit platelets, which is could be due to the the leucine to valine 
substitution at aa position 33. Here, however, mAb 26.4 and SZ21 show the same reduced 
binding. An important note is that for mAb 26.4 to bind with high affinity it needs a aspartic 
acid (D) at aa position 39 and a glutamine (Q) at aa position 470 and possibly others (5). Both 
positions are homologous is rabbit integrin β3. An alternative explanation could be simply 
that less platelets were in the rabbit platelet samples or that they were of lower viability 
reducing the overall integrin β3 HPA-1 antigen quantity. Nevertheless, the binding of mAb 
26.4 to rabbit platelets and presumably integrin β3, which has some overlap with the HPA-1 
epitope, gives an indication HPA-1a specific T-cells may be activated by rabbit platelets 




4.3 Is the antigen on rabbit platelets that activates HPA-1a-
specific T cells integrin β3? 
 
Our data suggests that HPA-1a may be activated by rabbit platelets/integrin β3 T-cell 
activation was measured. Here the main aim is to determine if HPA-1a specific T-cells are 
able to be activated by rabbit platelets and more interestingly if rabbit integrin β3 is the cause. 
T-cells activation assays were used to determine if DRB3-peptide (rabbit integrin)-HPA-1a 




HPA-1a specific antibodies bind rabbit platelets, one could argue that if antibodies and T 
cells are binding the same antigen, the antigen captured by these antibodies in rabbit platelet 




4.3.1 HPA-1a specific T-cell activation with 26.4 mAb linked Dynabeads 
bound HPA-1a or rabbit integrin presented by monocytes showed 
inconclusive results. 
 
The human HPA-1a+ and rabbit integrin β3 proteins bound on mAb 26.4-conjugated 
Dynabeads yielded inconsistent and unexpected results as both respective antigens caused 
little to no significant activation in T-cells. Both from theory as explained above, and from 
assay results of T-cell stimulation with peptide and with whole platelets from HPA-1a+ 
donors and rabbits , it may be assumed something has failed to work in Dynabeads protein 
binding or processing and presentation of antigen on beads by APCs. The method of using 
Dynabeads M-270 Epoxy as platform for antigen take up by monocytes T-cell activation in in 
viro cell culture assays has been successfully examined and used before (42). In theory the 
antigen bound to the 26.4 mAb-linked Dynabeads would be internalized by the monocytes, 
which would process the antigen into smaller peptides loaded into MHC II (DRB3*01:01). 
This means that even if the antigen (rabbit or HPA-1a integrin β3) is bound by 26.4 at the 
same epitope as our APCs MHC II would need to bind it, it wouldn’t interfere since the 
whole mAb-antigen complex is processed and dissociated. The problem thus likely lies 
elsewhere. The qualitative control of 26.4-linked Dynabeads did additionally show that 
Dynabeads were able to be conjugated with mAb 26.4 and subsequently with HPA-1a or 
rabbit integrin β3. This qualitative method of examining the conjugation of the antibody and 
binding of the antigen to Dynabeads is not able to quantify the amount of antigen bound to 
the beads with certainty. The problem may thus be that to little antigen was bound to the 
beads for monocytes to take up and significantly activate HPA-1a specific T-cells. This is 
also further supported by the fact HPA-1a antigen was able to stimulate D8T104 to a small 
degree. A possible factor for the low quantities of antigen bound on the Dynabeads could be 




protocol. The different lysis method may have affected or degraded the target proteins to a 
certain degree for example. In the future RIPA buffer should be used and possibly further 
protocol fine tuning could be performed to investigate the ability of rabbit or HPA-1a integrin 
β3 protein to stimulate HPA-1a specific T-cells.  
 
4.3.2 Rabbit integrin β3 antigen possibly has an equal ability to activate 
and cause proliferation in HPA-1a specific T-cells as HPA-1a 
antigen. 
 
To evaluate the reactiveness of HPA-1a specific T-cells to APC presenting rabbit integrin 
antigen (“peptide”, protein and whole platelet), TNF-α and proliferation assays were 
performed. The TNF-α assay measures immediate T-cell responses starting right after TCR 
activation by an appropriate antigen-MHC complex. Our results showed all blanks and 
negative controls without TNF-α expression, additionally stimulation with L33 peptide 
showed a response as expect from previous assays performed in our group (4). Also, we 
found that antigen from rabbit platelet lysate captured with anti-HPA-1a mAb 26.4 was able 
to stimulate a relatively weak TNF-α expression on HPA-1a specific T-cells. Furthermore, 
the captured antigen was also detectable with a second anti-HPA-1a mAb SZ21. This 
suggests that the isolated antigen recognized by HPA-1a- specific T-cells is rabbit integrin 
β3. Previously the peptide V33, being the L33 equivalent for rabbit integrin β3, been shown 
by M. T. Ahlen et.al, to induce TNF-α secretion with similar intensity to L33 (4). Since TNF-
α secretion in T-cell is an immediate response but not solely defining for a full T-cell 
response (43), to further support the hypothesis that rabbit integrin β3 can stimulate HPA-1a 
specific T-cells the proliferation was measured. The results show close to equal D8T104 
activation and proliferation by both monocyte presented human HPA-1a+ and rabbit platelets. 
Rabbit integrin β3 protein was not able to cause proliferation in D8T104 and HPA-1a only 
had a small population of proliferating T-cells, possibly due to low antigen amount captured 
on beads.  
It can be concluded that rabbit integrin β3 can cause activation of HPA-1a specific T-cells, as 
shown most conclusively from platelet derived antigens. And additionally, can show 
stimulation of T-cell both in short term (TNF-α excretion) and also in the long term 




now, to our knowledge, no other studies have been done activating HPA-1a specific T-cells 
with rabbit or more general animal antigen. Except, where a whole range of 12 aa long 
peptides with various aa substitutions were examined for their ability to activate HPA-1a 
specific T-cells as discussed above (4). Since rabbit integrin β3 antigen can be used to 
activate HPA-1a specific T-cells, the respective antigen may possibly also be used to induce 
tolerance in HPA-1a specific T-cells. Several tolerogenic immunological environments have 
been identified in the human body, like thymus, MALT, GALT and also certain mechanisms 
which can function throughout the body (12). Specifically the GALT is an interesting and 
also practical environment to examine tolerance induction for FNAIT, as the antigen only 
needs to be eaten, preferably in larger doses and possibly with adjuvants (29, 44-46). 
Tolerance induction via oral tolerance is mainly practical since rabbit is already commonly 
eaten and has thus been proven not to be a health hazard. However many different factors 
play a role in tolerance induction and it would need to be tested in the future in for example 
an animal model, to be come closer to a certain answer. Future perspectives on 
immunotherapies and in vivo testing, as well as a possible animal modal will be discussed 
later. 
 
4.4 Integrin β3 isolation by affinity filtration was not 
successful. 
 
As a measure of obtaining integrin β3 of HPA-1a or rabbit type a protocol was constructed 
using a size-exclusion pre-filtration column and an affinity isolation column with 26.4 linked 
CNBr activated sepharose resin. The obtained integrin β3 was then to be used in the TNF-α 
and proliferation assay, but we were unable to isolate enough target protein for detection and 
thus likely not enough for T-cell stimulation. The size-exclusion pre-filtration column was 
used to filter out salts and proteins under 30 kDa. The nanodrop results of the pre-filter 
fractions showed that molecules over 30 kDa exited the column first, as the bovine serum 
albumin (65 Da) peak overlapped the first peak of our platelet lysate sample. Protein smaller 
in size than 30 kDa are assumed to be the second peak and subsequent peaks are small 
molecules like salts as state by manufacturer (47). A western blot performed on the fractions 
taken after the void volume (first three fractions) showed that the target protein integrin β3 




affinity column has a capacity of ~7,3 mg of rabbit of HPA-1a integrin β3 (see appendix II – 
I), which is more than enough for T-cell stimulation. Additional calculation showed that 
approximately 22 µg of integrin β3 can be obtained/5 mL of rabbit or human blood (see 
appendix II – I)(14, 48). This showed that the affinity column has a high enough capacity for 
our purposes during this study, but that amount of integrin β3 present is low and only 3 
factors higher than the western blot detection limit (WB detection limit is 0,1 ng). Since, 
during this study, the main reason for starting protocol testing of integrin β3 was concept 
development the experiment was done anyway. Integrin β3 is estimated at a size of 90-110 
kDa from the GPIIIa subunit and the GPIIa with a heavy chain at 120 kDa and light chain at 
22 kDa linked by disulfide bonds. Dependent on a large number of variables are these subunit 
seen together or apart and can therefore vary widely in weight, anywhere from ~90 kDa to 
255 kDa (49). Rabbit integrin β3 is very similar in weight and subunit build-up although 
thought be 2-10 kDa heavier in general (50). A note to the comparison between western blot 
figures 4-5 and 4-13 where the integrin β3 sizes vary slightly. This was likely due to the 
beads with integrin bound being warmed to 70°C seen in figure 4-6  while the heavier 
integrin β3 in the isolate was not warmed at all. Western blot results of the fractions captured 
after the void fractions did not show any detectable levels of integrin β3, some integrin β3 
however was detected in the wash fractions and pre-filtrate fractions (Fig 4-13). Probable 
reasons for losing a factor 3 or more of target protein are likely to be dilation during the 
process of isolation, loss of target protein during the wash, target protein retention in the 
column during elution and/or varying platelet quality. The manufacturer of the CNBr 
activated sepharose resin also states larger quantities of protein are preferred as protein may 
be lost in the process due various reasons (51). For future application of this method, 
significantly larger volumes of platelet lysate should be used to negate losses during the 









4.5 Future perspectives 
 
4.5.1 Immune therapy through oral tolerance and it’s opportunities for 
optimization. 
 
As mentioned before in the introduction is there to this point still no treatment for FNAIT, 
prophylactic or therapeutic. A method that could potentially be used both as a prophylaxis 
before the onset of FNAIT and to lesser degree as therapeutic treatment during or for 
subsequent pregnancies could be of great interest. mAb 26.4 has and is being researched as a 
treatment for FNAIT in the form of blocking antibodies or antibody mediated immune 
suppression (5, 52). Rabbit integrin β3 however, has potential to be used as an antigen for 
oral tolerance induction in platelet, possible protein and also peptide forms as seen in this 
thesis and previous studies within our group (4). The rabbit platelets could for example be 
ingested by ingesting rabbit, its blood in some form or isolated rabbit integrin β3 protein, 
which is low impact for the patient. To be sure how effective this would be more study would 
need to be done, for example, if cooked rabbit would still have the intact L33 region, how 
much digestion affects the protein or if the dose of antigen would high enough. An interesting 
study that could be performed could also be to statistically analyse if communities regularly 
ingesting rabbit have lower occurrence of FNAIT than communities that do not normally eat 
rabbit.  
The results from this thesis can potentially be moulded into a plethora of different ways to 
adjust and make it more effective as an inducer of oral tolerance. A next step may be to 
research the effect of oral ingestion of rabbit β3 platelets or protein on HPA-1a tolerance in 










During the course of this 1 year master thesis aims were set as preparation and research into 
the potential of oral tolerance therapy (and other immunological therapies) using the HPA-1a 
antigen as means of tolerizing the patient to the respective antigen. The first aim was to 
ascertain if HPA-1a antibodies were specific to rabbit integrin β3 in protein, molecule (and 
peptide) form. This was done to determine if rabbit integrin β3 is similar enough in primary 
and tertiary protein structure to human HPA-1a+ integrin β3. Both analysis from protein 
databases and previous studies show promising similarity of the rabbit integrin β3 to HPA-1a, 
especially the 25-33 aa region. This finding was further confirmed by the antibody antigen 
binding assay, where HPA-1a-specific mAbs SZ21 and 26.4 bound significantly to rabbit 
integrin β3 on rabbit platelets. Since 26.4 mAb is specific, in part, for the same epitope as are 
HPA-1a specific T-cell, stimulation of HPA-1a-specific T cells with antigen captured by 
mAb 26.4 from rabbit platelet lysate lends support to the notion that these T cells are indeed 
activated by rabbit integrin β3.  
Rabbit integrin β3 antigen in peptide, (protein) and platelet form could be successfully used 
to activate HPA-1a specific T-cells and imitate immunization of mothers pregnant with a 
FNAIT afflicted child. Rabbit integrin may therefore be a realistic candidate for future 
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I - Calculation of affinity column capacity: 
- In the column ~5 mg of mAb 26.4 was used. Which was bound to the resin by the Fc 
region of the mAb and the mAb will thus have two binding regions. 
- mAb’s are approx. 150 kDa 




= 3.3 ∗ 10−8   
𝑚𝑎𝑠𝑠 𝑜𝑓 𝐻𝑃𝐴 − 1𝑎 𝑜𝑟 𝑟𝑎𝑏𝑏𝑖𝑡 𝑖𝑛𝑡𝑒𝑔𝑟𝑖𝑛 𝛽3 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑡𝑜 𝑏𝑖𝑛𝑑
= (3.3 ∗ 10−8 ∗ 2) ∗ 110.000 = ~0,0073 𝑔𝑟𝑎𝑚 → ~𝟕, 𝟑 𝒎𝒈 
II - Calculation of protein we expect in our platelet sample: 
- both human and rabbit platelets have ~80.000 molecules of integrin β3 on its 
surface/platelet (14, 48). There is about 300*109 platelets/liter of blood in both human and 
rabbits → we use around 5 mL of blood per isolation cycle.  
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑖𝑛𝑡𝑒𝑔𝑟𝑖𝑛 𝛽3 𝑝𝑒𝑟 5 𝑚𝐿 𝑜𝑓 𝑏𝑙𝑜𝑜𝑑 = 300 ∗
109
1000
∗ 5𝑚𝐿 ∗ 80.000
= 120.000 ∗ 109 𝑝𝑙𝑡 → 𝑡𝑜 𝑚𝑜𝑙 = 1,99 ×  10−10 𝑚𝑜𝑙 
𝑅𝑎𝑏𝑏𝑖𝑡 𝑖𝑛𝑡𝑒𝑔𝑟𝑖𝑛 𝛽3 𝑚𝑎𝑠𝑠 𝑝𝑒𝑟 5 𝑚𝐿 𝑏𝑙𝑜𝑜𝑑 = 1,99 ×  10−10 𝑚𝑜𝑙 ∗ 110.000 =







II Additional information 
 
I - Method for HPA-1a/rabbit integrin β3 isolation with a size-exclusion and affinity 




Figure Appendix 1 schematic of the HPA-1a/ rabbit integrin β isolation setup. 
Platelet lysate of rabbit or HPA-1a type is prefiltered in a column containing Size-exclusion resin called Sephadex G50. 1. This resin has small holes through 
which mainly the molecules under 30 kDa can travel (small molecules in green). Bigger molecules do not enter the holes of the resin and have therefor a quicker 
path through the resin (medium and big molecules in blue and orange). A The big molecules over 30 kDa will exit the column first. B The fractions are measure 
with nanodrop for protein concentration and the fractions containing the first peak in protein concentration are entered in to the affinity column. 2. The HPA-1a 
and rabbit integrin β3 will bind the 26.4 linked CNBr-activated resin while all other proteins will exit the column by washing. C After washing the column is 




II - Increased loading stability of Peptides in MHC II on B-LCL enables T-cell 
activation by L33 but not LolP1. 
 
Previously the loading stability and thus the quantity of MHC II loaded peptide was assessed 
in B-LCL’s in the presence or absence of Adamantane Ethanol. LolP1 and L33 peptides were 
loaded into B-LCL MHC II by a 4 hour coincubation with Adamantane Ethanol or DMSO in 
the controls. Some B-LCL were then used for a peptide loading quantification by flow 
cytometry (Section 4.2.1). With the remaining B-LCL’s a CFSE proliferation assay was 
performed if a significant difference in HPA-1a specific T-cell activation could be detected. 
In figure appendix 3 the HPA-1a specific T-cell clone D8T104 is represented in 4 flow 
cytometry histograms. D8T104 was incubated with B-LCLs pulsed with negative control 
peptide LolP1 with or without AdEtOH (left top and bottom Fig 4-3) . Both respective 
D8T104 population only showed the brightly CFSE-stained population with no populations 
with decreased CFSE fluorophore intensity indicating no proliferation. L33 pulsed B-LCL’s 
can be seen on the right, where AdEtOH-less pulsing showed no populations decreased in 
CFSE intensity. However L33 pulsed B-LCL’s in the presence of AdEtOH did show 1 to 2 
D8T104 populations with decreased CFSE intensity, indicative for T-cell proliferation (Fig 4-
3 lower right histogram). Indicating that AdEtOH increased loading stability in B-LCL 
enabled T-cell activation by L33 presentation but not lolP1, while non AdEtOH treated B-









Figure Appendix 3 Proliferation assay with D8T104 T-cell clone incubated with B-LCL’s pulsed with control peptide lolP1 or 
L33 with AdEtOH present or absent.  
The T-cells activation was assessed by a CFSE proliferation assay to determine the positive or negative effect of increased peptide 
loading through added AdEtOH. The top left shows the D8T104 population incubated with B-LCL pulsed with LolP1 in absence of 
AdEtOH. The lower left shows the D8T104 population incubated with B-LCL pulsed with LolP1 in presence of AdEtOH. The top 
right histogram shows the D8T104 population incubated with B-LCL pulsed with L33 in absence of AdEtOH. The lower right shows 
the D8T104 population incubated with B-LCL pulsed with L33 in presence of AdEtOH, with the parent as well as 2 daughter 
populations. CFSE intensity is presented on the X-axis and cell count on the Y-axis. 
 
 
Figure 6-1 Western blot of Dynabeads conjugated with 26.4 and incubated with either rabbit or HPA-1a integrin showed 
significant binding of the respective integrin types.  
Rabbit and HPA-1a integrin from respectively rabbit and human HPA-1aa+ donors platelets lysate was captured on 26.4 
conjugated Dynabeads. The beads were analyzed under reducing conditions on a western blot. The western blot showed several 
strong bands at 57 kDa, and weaker bands at 120 kDa, 80 kDa, 55 kDa, 48 kDa, 33 kDa and 27 kDa for the samples in blot A. The 
western blot B showed one band at 50 kDa and 25 kDa only in the beads 26.4 10 µL sample. For both western blot MagicMark XP 
western protein standard were used.Figure 6-2 Proliferation assay with D8T104 T-cell clone incubated with B-LCL’s pulsed with 
control peptide lolP1 or L33 with AdEtOH present or absent.  
The T-cells activation was assessed by a CFSE proliferation assay to determine the positive or negative effect of increased peptide 
loading through added AdEtOH. The top left shows the D8T104 population incubated with B-LCL pulsed with LolP1 in absence of 
AdEtOH. The lower left shows the D8T104 population incubated with B-LCL pulsed with LolP1 in presence of AdEtOH. The top 




Appendix Table 1 Media, buffers, materials and reagents used during this study. 
 





PBS + 0.2% Bovine Serum Albumin 
(PBSA 0.2%) 
 
In house (UNN) Washing, flow 
cytometry 






HPA-1a- plasma Blood donor blood 
bank UNN Tromsø 
Cell culture 

















CFSE, CellTrace Thermo Fisher Staining for flow 
cytometry 






Lymphoprep TM Axis-Shield 
(Dundee, Great 
Britain) 
Density gradient for 
fractioning of whole 
blood or buffy coat 
Anti-CD3 Ab 
 
Thermo Fisher Cell culture 
PHA (R30852801) 
 
Thermo Fisher Cell culture 
Adamantane ethanol 
 
 B-cell pulsing 
UltraComp eBeads 
 
Thermo Fisher Flow cytometry 
Dynabeads antibody coupling kit Novex life science Beads coupling 
Dynabeads M-270 Epoxy Novex life science Beads antigen pulsing 





EDTA  HPA-1a antibody assay 
Sodium Azide  Antibody/peptide 
storage 
TRITION X-100  Cell lysis 
TAPI-0  TNF-α 
Sephadex G50 superfine GE healthcare Protein isolation 
MilliQ water In house Protein isolation 
Ethanol  Protein isolation 
CNBr- activated Sepharose 4B GE healthcare Protein isolation 
HCl  Protein isolation 




NaCl  Protein isolation 
Tris-HCl  Protein isolation 
Acetate buffer  Protein isolation 
Protease inhibitor cOmplete Roche Protein isolation 
Tris  Protein isolation 
trisodium citrate dehydrate  Protein isolation 
NuPAGE 4x LDS Sample Buffer Novex SDS-PAGE 
NuPAGE 10x Sample Reducing 
Agent 
Novex SDS-PAGE 
20x NuPAGE Running buffer Novex SDS-PAGE 
NuPAGE® Novex® 4-12% Bis-Tris 
Gels 
Novex SDS-PAGE 
SimplyBlue SafeStain  SDS-PAGE 
HRP  WB 
MagicMark XP western protein 
standard 
Invitrogen  WB 
Invitrolon PVDF Filter Paper 
Sandwich 0.45 um Pore Size 
Invitrogen WB 
NuPAGE 20x Transfer Buffer Invitrogen WB 
SuperBlock (PBS) Blocking Buffer Thermo Scientific WB 
blocking reagent Thermo Scientific WB 
PBS 0.05% Tween 20 In house WB 
SuperSignal West Femto Maximum 
Sensitivity Substrate 
Thermo Scientific WB 
 
 
 
 
 
 
 
 
